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Executive Summary 
This report summarizes 4 years of research achievements in this Office of Science (BER), 
U.S. Department of Energy (DOE) project. The research described was conducted by scientists 
and supporting staff at Lovelace Respiratory Research Institute (LRRI)/Lovelace Biomedical and 
Environmental Research Institute (LBERI) and the Southern Urals Biophysics Institute (SUBI). 
All project objectives and goals have been achieved. A major focus was on obtaining improved 
risk estimates for deleterious effects of exposure via inhalation to plutonium (Pu) isotopes in the 
workplace (DOE radiation workers) and environment (public exposures to Pu-contaminated 
soil). To achieve project goals, a considerable effort was devoted to obtaining improved 
estimates of cancer risk associated with chronic exposure at low rates to alpha radiation alone 
or in combination with gamma rays. Dose-response modeling and epidemiological studies 
(Mayak plutonium facility worker population) were conducted. With the dose-response modeling, 
numerous published data on radiobiological effects from the molecular/cellular to the 
organ/tissue levels were acquired along with data from our epidemiological studies of lung and 
liver cancer among Pu-exposed humans as well as from many other epidemiological and 
ecological studies. The large number of data sets acquired were evaluated to determine 
whether they supported the linear-no-threshold (LNT) cancer risk model that drives current, low-
dose radiation risk assessment and is the basis for establishing radiation exposure limits for 
humans and for establishing radionuclide soil action levels (RSALs) for radionuclide-
contaminated soils.  
Based on the LNT risk assessment paradigm, any amount of ionizing radiation exposure 
to DOE radiation workers or the public is expected to harm some among any large irradiated 
population, irrespective of the makeup of the population or the physical characteristic of the 
radiation. Our very significant findings were as follows: low doses and dose rates of sparsely 
ionizing radiation (e.g., X-rays, gamma rays, beta particles) activate a system of protective 
processes that include p53-related DNA repair/apoptosis, an auxiliary form of apoptosis 
(presumably p53-independent) that removes precancerous and other aberrance cells, and 
enhance immune functions (which contribute to suppressing cancer occurrence). We call this 
radiation activated natural protection (ANP). The level of ANP appears to increase with age and 
may provide little benefit to most children. The increased protection with age is considered to 
relate to an increase in the body’s genomic instability burden, with protective signaling 
increasing as the number of unstable cells (which participate in the cross talk with normal cells 
to trigger removal of the aberrant cells) in the body increase. High radiation doses and dose 
rates appear to inhibit or suppress protective signaling. However, for sparsely ionizing radiation 
forms, reducing dose rate and extending the period over which the radiation dose is delivered 
appears to increase the protection efficiency and extend the range of protective doses. Alpha 
radiation by itself does not appear to induce any significant protection against spontaneous 
cancers. 
For combined extended exposure at low rates to alpha radiation and low-dose gamma 
rays, gamma-ray ANP can completely suppress cancer induction by low-dose alpha radiation. 
However, high doses of alpha radiation appear to inhibit low-dose gamma-ray ANP. For high 
alpha radiation doses, lung cancer relative risk (RR) appears to approach a plateau rather than 
to continue to increase as dose further increases. 
To incorporate this new knowledge into low-dose cancer risk assessment, we developed a 
biological-based cancer RR model. The model allows for an ANP-related reduction in cancer 
risk at low doses to below the spontaneous level and for gamma-ray ANP against alpha-
radiation-induced cancer. Dose-response curves for which cancer RR first decreases to below 1 
at low doses and then increases to above 1 at moderate and high doses are called hormetic. 
Thus, our model is called a hormetic RR (HRR) model. With the HRR model, there is a range of 
low doses from just above natural background radiation exposure over which ANP is maximal. 
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This dose range is called the Zone of Maximal Protection. For this dose zone, RR ≈ 1 – 
PROFAC (protection factor), where the PROFAC gives the expected proportion of protected 
individuals (i.e., those with ANP) that do not develop cancer that would have otherwise 
developed cancer in the absence of radiation exposure. Our research found values of PROFAC 
against cancer ranging from about 0.1 (10% protected from cancer) up to 1.0 (100% protected 
from cancer in one rat study involving combined exposure to alpha and gamma radiation). 
In circumstances where only alpha radiation is involved, PROFAC appears to be 0 (or 
very close to zero). However, natural background low linear energy transfer (LET) radiation 
exposure over an extended period and exposure to diagnostic X-rays could stimulate protecting 
signaling, leading to a small PROFAC. Repeated exposures to diagnostic X-rays therefore could 
significantly suppress lung cancer induction due to chronic exposure to low doses of alpha 
radiation from previously inhaled plutonium isotopes. Some Mayak plutonium facility workers 
who inhaled the alpha-emitter plutonium-239 (239Pu) were also exposed over an extended 
period (years) to low doses and dose rates of gamma rays. Our analysis of data from a cohort 
study that used external controls revealed significant gamma-ray ANP against lung cancer 
(PROFAC = 0.86 ± 0.07). 
In our extensive review of adaptive response research results, we found that low-dose-
radiation ANP has been demonstrated to: 
• Protect against chromosomal damage! 
• Protect against mutation induction by a high radiation dose if given before or after the 
high dose! 
• Eliminate precancerous (neoplastically transformed) cells! 
• Prevent chemically induced cancer! 
• Prevent low-dose, alpha-radiation-induced cancer! 
• Suppress metastasis of existing cancer! 
• Protect against diseases other than cancer! 
• Improve the efficacy of combined high-dose radiation plus gene therapy for cancer! 
• Extend the lifespan of cancer-prone mammals! 
It can now be stated with confidence that the LNT model does not apply to many real-
world radiation-exposure scenarios, especially when adult humans are involved and when low-
doses and dose rate of low-LET radiation occur alone or in combination with low doses of alpha 
radiation. These finding have important implications for regulating radiation exposure of workers 
and the public and for establishing RSALs for Pu-contaminated sites. Recommendations are 
made for adjusting current RSALs to account for low-dose, low-LET-radiation ANP. 
After the death of Mr. Alexander Litvinenko last November in London due to exposure to 
polonium-210 (210Po), we began quickly modeling the toxicity to humans for this largely forgotten 
alpha-emitting radioisotope using our hazard-function model. We collaborated with other 
radiation research experts from around the world, including scientist at the Health Protection 
Agency (HPA) in London responsible for managing the incident. Our research findings are 
discussed in two publications on 210Po toxicity that have been widely circulated. Key information 
related to 210Po toxicity to humans was also provided to ABC News at their request. 
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1. Research Objectives (modified since project start date) 
This project had the following four objectives: 
1. To use available data from studies of Russians exposed by inhalation to plutonium-
239 (239Pu) (insoluble and soluble forms) and standard and novel analytical methods 
to develop improved characterization of health risks to the public from inhaled 
plutonium (Pu)-contaminated soil from pre- and post-remediated U.S. Department of 
Energy (DOE) sites. 
2. To use available data from studies of Russians exposed to 239Pu and standard and 
novel analytical methods to develop improved characterization of health risks to 
DOE workers who inhaled airborne weapons grade (WG) Pu in dioxide form during 
decontamination and decommissioning (D&D) operations. 
3. To develop improved biodosimetry capabilities for evaluating Pu intake based on 
clinical data for Russians who inhaled plutonium-239 dioxide (239PuO2). (Work 
completed in year 1 with carryover funds). 
4. To continue to provide educational material about radiation and radiation issues to 
the public and others via our project-related website: www.radiation-scott.org. 
The following two goals were originally stated in our previous renewal application but 
because the requested funding was significantly reduced, the goals were unachievable with the 
funding level provided: 
• To contribute significantly to improving the probabilistic approach for selecting 
radionuclide soil action levels (RSALs) for sites where soil is contaminated with Pu 
(e.g., Rocky Flats Environmental Technology Site). 
• To design a reliable system of respirator protection for workers involved in D&D work 
for the DOE at Pu-contaminated sites. 
2. Background 
Research in this project has benefited from numerous publications (over 350) in different 
research areas, including radiobiological, biomathematical/statistical, dosimetric, and 
epidemiological/ecological research (Section 17, References). The main section of this report 
provides, in addition to background information on sources of ionizing radiation exposure and 
associated stochastic radiobiological effects, a description of research conducted and key 
findings. The main section is supported by three appendices (A – C). Appendix A presents key 
results from our previous project (under the same title as this renewal project) that relate to the 
stochastic deposition of insoluble plutonium dioxide (PuO2) aerosols in the respiratory tract of 
adult radiation workers and that relate to measured aerosol filter penetrations by high density 
metal aerosols used as surrogates for PuO2.  Appendix B provides an in press paper by Scott 
(2007d) which proposes a new approach to regulating radiation exposure of humans that allows 
for adaptive-response-related thresholds doses for harm. Appendix C provides a submitted 
paper by Scott (2007e) demonstrating the efficient prevention of alpha-radiation-induced lung 
cancer by extended, low-rate exposure to low doses of gamma rays, which has important 
implications for establishing RSALs and for regulation exposure to Pu and other alpha emitting 
isotopes. A published paper by Scott and Di Palma (2006) relates to our modeling of cancer 
relative risk (RR) and accounting for radiation adaptive response (also called hormesis).  
The indicated numerous publications (Section 17, References) related to the research 
carried out in this project include publications on radiation research (experimental and 
theoretical) at the molecular, cellular, organ/tissue, systemic, organism, and population levels as 
well as methods of analysis and integration of results from such studies over multiples biological 
scales. In carrying out our research, we reviewed previous health-risk-assessment-related, 
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dose-response modeling efforts that span biological scales from the molecular to the organism 
levels, as well as the current state of knowledge about the consequences of humans and other 
mammals being exposed to ionizing radiation. Such information is essential for understanding 
the true health risk to humans in the workplace (e.g., DOE radiation workers) and elsewhere 
from exposure to low and high levels of ionizing radiation, including alpha radiation from Pu 
isotopes. While our main focus has been on high linear-energy-transfer (LET) alpha radiation, 
considerable research has also addressed combined exposure to low- and high-LET radiations 
and exposure to only low-LET radiation. This is especially important in that exposure to high-
LET alpha radiation is most often accompanied by exposure to low-LET radiation (e.g., as for 
radon in the home and for plutonium workers). Further, there is now abundant evidence for low-
LET radiation activated natural protection (ANP) against cancer and other genomic instability 
diseases, including protection against alpha-radiation-induced cancer (Scott and Di Palma 
2006; Scott 2007a,b,c). 
Some background information is provided below on (1) the ionizing radiation environment 
on earth, including environmental Pu isotopes, (2) composition of weapons grade plutonium 
(WG Pu); (3) the current low-dose risk-assessment paradigm and associated controversy; (4) 
stochastic radiobiological processes and associated effects; and (5) low-dose, low-LET radiation 
ANP against cancer and other genomic-instability-associated diseases. 
2.1 The Ionizing Radiation Environment on Earth 
Natural background ionizing radiation on earth comes from the following three sources 
(Figure 1): the sun (solar radiation), outer space (cosmic rays), and terrestrial (e.g., 
radionuclides in our bodies and environment, and radon in the home). All organisms on earth 
are constantly bombarded by cosmic, solar, and terrestrial radiation sources. Our food, water, 
and air we inhale all contain radionuclides. Other sources of ionizing radiation exposure include 
diagnostic medical procedures (X-rays, isotopes used in nuclear medicine), televisions, smoke 
detectors, weapons fallout, and radioactive waste (Figure 2). 
2.1.1 High- and Low-LET Radiations 
Two types of radiation (high and low LET) are usually distinguished when characterizing 
radiation risks to humans. High-LET forms include alpha particles, neutrons, and heavy ions that 
produce intense ionization patterns when interacting with biological tissue. Considerable energy 
is deposited when traversing a narrow thickness of tissue. Low-LET forms include X- and 
gamma rays and beta particles that deposit far less energy when traversing a narrow thickness 
of tissue. 
Radioactive Soil and Rocks
Plant
s
Our Bodies
Indoor RadonThe Sun
Plants
Radiation Sources are Everywhere
Figure 1.  Natural radiation sources.
• X-ray machines
• Medical isotopes
• Televisions
• Smoke detectors
• Weapons fallout
• Radioactive waste
Man-made Radiation Sources
Figure 2.  Other sources of radiation exposure.
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2.1.2 Units for Expressing Radiation Doses 
Radiation dose is expressed in different ways depending on the intended usage. A 
fundamental unit is the absorbed radiation dose, which is a measure of energy deposited in 
tissue (or other material) divided by the mass irradiated. Typical units of absorbed dose are the 
gray (Gy) which is equal to 1 joule/kg, and the milligray (mGy), which is one thousandth of a 
gray. These units can be applied when characterizing any type of radiobiological damage. 
For regulating radiation exposure of humans (e.g., setting radiation exposure limits), 
establishing RSALs (and related remediation standards), and for low-dose cancer risk 
assessment, special radiation dose units have been established that are based on the linear-no-
threshold (LNT) hypothesis (discussed in Section 2.2). These units are the result of applying 
statistical weights called radiation weighting factors (WR) to radiation-specific doses and are 
expressed in units such as the sieverts (Sv) and millisieverts (mSv). These weighted doses are 
called equivalent doses and can be added for a given tissue. To account for differing 
sensitivities of different tissues, a second set of weights called tissue weighting factors (WT) are 
employed to the equivalent doses. The resulting doubly weighted doses can also be added and 
the resultant dose is called effective dose and also expressed in sieverts or millisieverts. Under 
presumed LNT radiation dose-response functions for all cancer types, the effective dose 
represents the uniform gamma-ray dose to the total body that would incur the same overall 
cancer risk as is associated with the person’s actual exposure, irrespective of its nonuniformity 
and irrespective of the types and energies of the radiations that are involved. Radiation dose 
limits are based on these weighted doses and the LNT risk assessment paradigm. Later, 
evidence pointing to a need to replace this approach with a more scientifically valid one is 
presented and an alternative regulatory paradigm is proposed in Appendix B. 
2.1.3 Current Radiation Dose Limits 
As already indicated, human radiation exposures are limited for nuclear workers, the 
public, and other groups based on restricting the effective dose. For example, the effective dose 
limit for nuclear workers is 50 mSv/y and 1 mSv/y for the public and is based on U.S. DOE and 
Nuclear Regulatory Commission regulatory policies (Metting 2005). The U.S. Environmental 
Protection Agency’s regulatory policy limits on release of radioactivity to air is based on limiting 
the effective dose to humans to 0.1 mSv/y, and for public drinking water the corresponding limit 
is 0.04 mSv/y. For a point of reference, natural background radiation doses in the United States 
are associated with an effective dose of about 3 mSv/y (radon exposure included) (Metting 
2005). For Ramsar, Iran, the corresponding dose associated with natural background radiation 
is about 200 mSv/y. Interestingly, such high background radiation doses appear to be 
associated with radiation hormesis-related protection against cancer (Frigèrio and Stowe 1976; 
Nambi and Soman 1987), i.e., a reduction in cancers. Similar reductions have been reported for 
lung and other cancers based on many epidemiological/ecological studies (Sanders and Scott 
2007; Scott and Di Palma 2006). 
2.2 LNT Risk-Assessment Paradigm and Associated Controversy 
As previously indicated, the current low-radiation-dose, risk-assessment paradigm is 
based on the LNT hypothesis (Figure 3), which states that any increment of ionizing radiation 
dose can harm humans and other mammals via inducing stochastic effects such as cancer, and 
the risk for stochastic effects increases as an LNT function of radiation dose (NCRP 2001a; 
NRC 2005). The LNT assumption implicates possible harm from the smallest of ionizing 
radiation exposures, including natural background radiation exposure. Cancer risk estimates 
under the LNT hypothesis are largely derived based on victims of the atomic bombings in 
Hiroshima and Nagasaki. Cancer risk estimates derived from the very high-rate exposures and 
moderate and high doses that occurred are extrapolated to low doses using an LNT function 
(Figure 3). Corresponding risk estimates for low doses and dose rates (many orders of 
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magnitude lower rates than for the A-bombs) are obtained via use of what is called a low dose 
and dose rate effectiveness factor (DDREF). The DDREF is usually assigned the very small 
value of 2 (which may be appropriate for DNA repair effects) and is used to reduce the risk (or 
slope of the dose-response curve) by that amount to supposedly account for a lowered risk after 
low dose rates, regardless of how low the dose rate actually is. It is interesting that all of the 
complex biology associated with radiation-induced stochastic effects is presumed by many to be 
accounted for by the DDREF. Protective processes such as elimination of aberrant cells via 
apoptosis (Portess et al. 2007) and cancer suppression via immune system functions (Liu 2007) 
is totally disregarded.  
 
Figure 3.  Linear-no-threshold/low-dose low-dose-rate approach to cancer risk assessment. The 
approach precludes demonstrating adaptive response (hormesis) and uses what has been called 
utopian-world radiation dose units, which are based on the make-belief that a linear-no-threshold risk 
function is valid for all radiation types and exposures. 
We later show low-dose-rate data (many orders of magnitude lower dose rate than for the 
Hiroshima and Nagasaki bombs) where cancer risk is actually suppressed significantly below 
the spontaneous level, which cannot be accounted for with the utopian-world LNT/DDREF 
approach to low-dose risk assessment indicated in Figure 3. 
The BEIR VII Report (NRC 2005) and the earlier NCRP Report 136 (NCRP 2001a) both 
recommended the continued use of the LNT supposition (any amount of radiation harms 
someone among a large population). However as we show in Appendices B and C, the LNT risk 
assessment practice appears to be incorrect for low-dose radiation exposures when involving 
low-LET forms or combinations of low- and high-LET forms. In fact, use of the LNT supposition 
is contributing to the waste of possibly billions of dollars related to excessive environmental 
remediation. Further, radiation phobia driven by the LNT risk perspective is likely to cause far 
more real casualties in the event of radiological terrorist act involving a dirty bomb than are likely 
to be related to actual radiation exposure (Figure 4). For a point of reference, LNT-driven 
radiation phobia was responsible for the loss of more than 100,000 lives through abortions in 
Eastern Europe following the Chernobyl accident (Ketchum 1987). 
Current Radiation Risk Assessment 
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Figure 4.  LNT-idea driven radiation phobia is likely to cause more casualties following a dirty 
bomb incident than are associated with actual harm from radiation exposures. 
Radiobiological research carried out by numerous groups worldwide collectively does not 
support the LNT hypothesis for low-LET radiation (Ducoff 1975; Hoel et al. 1983; Bogen 1989; 
Azzam et al.1994,1996; Pollycove 1995; Mitchel et al. 1997; Redpath et al. 1998, 2001; Hoel 
and Lei 1998; Yamamato et al. 1998; Kondo 1999; Feinendegen et al. 1999, 2000; Pollycove 
and Feinendegen 1999, 2001;Yamamato and Seyama 2000; Feinendegen and Pollycove 2001; 
Bonner 2003; Hooker et al. 2004; Higson 2004; Sanders 2007; Sanders and Scott 2007; Scott 
2007a,b,c ). The recent report of the French Academies that addressed the validity of the LNT 
idea (Tubiana 2005; Tubiana et. al. 2005, 2006; Tubiana and Aurengo 2006) clearly articulated 
the lack of support. The French Academies report concludes the following:  
“… this report raises doubts on the validity of using LNT for evaluating the carcinogenic risk of 
low doses (< 100 mSv) and even more for very low doses (< 10 mSv).” 
The French Academies therefore came to a very different conclusion than was presented 
in the BEIR VII and NCRP 136 reports regarding the validity of the LNT model. Thus, the 
appropriateness of the current low-dose radiation risk assessment practice that is based on the 
LNT idea remains quite controversial. Research (modeling and epidemiological) conducted in 
this project has contributed significantly toward helping clarify when and when not LNT might be 
expected to apply. It would be expected to apply when humans at any age are exposed only to 
alpha radiation.  However, when exposed to sparsely ionizing radiation (e.g., X-rays, beta 
particles, or gamma rays, or their combinations) LNT would not be expected to apply to persons 
already possessing a significant genomic instability burden (Scott and Di Palma 2006). A 
human’s genomic instability burden increases with age and also with exposure to genotoxic 
agents in the environment, in the home, and in the workplace. Protective processes discussed 
in Section 2.4 can eliminate cells with genomic instability (e.g., precancerous cells). The 
protective processes can be stimulated by low doses and dose rate of sparsely ionizing 
radiation (Scott and Di Palma 2006)! When this occurs, benefit rather than harm is expected to 
be associated with the radiation exposure. 
2.3 Stochastic Radiobiological Processes and Effects 
Radiation-induced cancer is considered a stochastic effect (i.e., has a unknown probability 
of occurrence, but the probability can be estimated). Our research has focused on improved 
estimates of cancer risk after exposures to low doses of ionizing radiation, including alpha 
LNT-Associated Radiation Phobia 
Following a Dirty Bomb Incident
Radiation-Phobia-Associated Impacts:
• Loss of lives associated with frantic evacuations.
• Severe injuries during evacuations.
• Increased suicides and abortions.
• Increased psychosomatic disorders.
• Increased drug/alcohol/cigarette abuse.
• Permanent abandonment of properties                 
with low-level contamination.
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radiation from inhaled alpha-emitting Pu isotopes and after combined exposure to alpha and 
gamma radiations. It is not widely known that radon exposure in the home involves combined 
exposure to alpha and gamma radiations.  
Our risk modeling is biologically based and supported by epidemiological studies. In 
developing our biologically based cancer risk model for radiation exposure, we have considered 
the complex stochastic processes involved and the related biological outcomes. We also 
reviewed other quantitative models that describe both stochastic and deterministic biological 
effects caused by radiation or other toxicants (Whittemore and Keller 1978; Zaider and Rossi 
1980; Barrett and Wiseman 1987; Bond et al. 1987; Brenner et al. 2001; Burkart et al. 1997; 
Calabrese and Baldwin 1999; Calkins 1971; Cucinotta et al., 2002; Elkind 1991, 1994;Crawford-
Brown and Hofmann 1993; Feinendegen et al. 1999, 2000; Feinendegen and Pollycove 2001; 
Heidenreich et al. 1997; Hoel et al. 1983; Joiner et al. 1999; Luebeck et al. 1996; Moolgavkar 
et al. 1993; NCRP 2001a; Pollycove 1995; Pollycove and Feinendegen 1999, 2001; Portier 
1987; Portier et al. 1990; Schöllnberger et al. 2001a-c; Scott 1981, 1983, 1984, 1986, 2004b, 
2005c, 2007f; Scott and Dillehay 1990; Stewart 1999; Trott and Roseman 2000; Okladnikova 
et al. 2005a,b,c). This review helped to guide the cancer risk modeling conducted in this project.  
Our cancer risk modeling was also supplemented by some modeling of radiation-induced 
deterministic effects (acute lethality). This modeling proved to be quite beneficial following the 
polonium-210 (210Po) poisoning event that occurred during November 2006 in London. Our 
modeling of radiation deterministic effects risks help to clarify the likely intake of 210Po by Mr. 
Alexander Litvinenko for the British Health Protection Agency (Harrison et al. 2007; Scott 
2007f). 
For low-dose radiation risk assessment, quite a lot is known about stochastic processes 
associated with radiobiological responses in vivo and in vitro. A key stochastic process is the 
induction of genomic instability (Kadhim et al. 1992, 1994, 1995, 1996, 1998; Kennedy et al. 
1996; Little 1985, 1999; Little et al. 1990; Mauder and Morgan 1993; Morgan et al. 1996; 
Martins et al. 1993; Mothersill and Seymour 1998a,b; Wright 1998). A second key stochastic 
process relates to the occurrence of bystander effects, generally thought of as deleterious 
effects, based mainly on high-LET radiation studies (Brenner et al. 2001; Hei et al. 1997; Iyer 
and Lehnert 2002a,b; Little et al. 2002; Lyng et al. 2000; Mothersill and Seymour 1997, 1998a,b; 
Nagasawa et al. 2002;  Seymour and Mothersill 2000). For low-LET radiation, the bystander 
effect has been found to be generally protective (Hooker et al. 2004, Redpath et al. 2001, Scott 
2007a-c). A third key stochastic process is radiation adaptation, which is a form of hormesis (Liu 
2007; Rithidech and Scott 2007; Redpath and Elmore 2007; Sanders 2007; Scott et al. 2007). A 
key stochastic effect at the cellular level associated with the indicated stochastic processes is 
the occurrence of genomically unstable cells (e.g., mutants and neoplastically transformed 
cells). Studies of neoplastic transformation (occurrence of precancerous cells) in vitro (Azzam 
et al. 1994, 1996; Ottolenghi et al. 1994; Redpath and Antoniono 1998; Redpath et al. 2001; 
Scott 1997; Scott et al. 2003) have provided useful information regarding the general shape of 
the dose-response curve for low-dose/dose-rate radiation-induced cancer.  
Numerous researchers have attempted to link radiation-induced stochastic effects at the 
cellular level to cancer occurrence in humans by considering the general stages of initiation, 
promotion, and progression (Armitage and Doll 1954; Crawford-Brown and Hofmann 2002; Hoel 
and Li 1998; Kondo 1999; Mebust et al. 2002; Moolgavkar et al. 1993; Rossi and Zaider 1997; 
Tan 1991; Thorslund et al. 1987; Trott and Roseman 2000). However, these models did not 
adequately integrate the currently known underlying biological mechanisms of genomic 
instability, adaptive response, and bystander effects. We therefore developed a biologically 
based cancer RR model as a result of having carried out the indicated multi-scale integration via 
assuming a proportionality between cancer and neoplastic transformation RR (Scott 2007a,b,c).  
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2.4 System of Natural Protective Processes and the Control of Genomic Instability and Its 
Deleterious Consequences 
Mammalian cellular communities are not complacent when threatened by environmental 
stresses such as ionizing radiation. The community reacts through a system of protective 
processes (when they are activated/stimulated by low doses of radiation) to limit deleterious 
biological consequences of irradiation (e.g., instability in the genome, mutations, neoplastic 
transformations, and cancer occurrence) (Makinodan and James 1990; Liu et al. 1994a,b; Liu, 
2003, 2004; Sakai et al. 2003; Feinendegen et al. 2004; Scott 2004a; Lombard et al. 2005; 
Coates et al. 2005; Ljungman 2005). The protective processes include (1) detecting (sensing) 
DNA damage; (2) correcting the damage after its detection via activated low- or high-fidelity 
DNA repair; (3) removing cells with residual DNA damage (e.g., damaged cells that fail to 
undergo repair or misrepair their DNA damage) via apoptosis; and (4) stimulated immune 
functions. 
DNA double-strand breaks may be the most disruptive form of damage to nuclear DNA 
(Chu 1997). They may occur by extrinsic insult from environmental sources or intrinsically as a 
result of cellular metabolism or a genetic program (Mills et al. 2003). Double-strand breaks are 
repaired by homologous recombination and by nonhomologous end-joining (Thompson and 
Schild 1999, 2001), which is the predominant mechanism in eukaryotes (Mills et al. 2003). 
Misrepair of DNA damage can lead to mutations and associated genomic instability (Tubiana 
et al. 2005). Cells that do not undergo p53-related repair of DNA damage can also be eliminated 
via p53-related apoptosis (Rothkamm and Löbrich 2003). An auxiliary protective apoptosis 
mediated (PAM) process has also been described (Portess et al. 2007), partly due to research 
we carried out at our Institute (Scott et al. 2003; Scott 2004a). The PAM process seems to play 
a role in removing cells that develop genomic instability as a result of having undergone viable 
misrepair of DNA damage. This auxiliary protection, like repair of DNA double-strand breaks, 
appears to require a threshold level of mild stress, which seems to be caused by low doses 
(above an individual-specific threshold) of low-LET radiation forms such as X rays, gamma ray, 
and beta radiation (Scott et al. 2007).  
Others have also proposed (Hanahan and Weinberg 2000; Tubiana et al. 2005) that 
apoptosis protects from stochastic effects such as cancer via eliminating genomically unstable 
cells. Hanahan and Weinberg (2000) in their classic paper entitled “The Hallmarks of Cancer” 
pointed out the following: “Collectively, the data indicate that the cell’s apoptotic program can be 
triggered by an over-expressed oncogene. Indeed, elimination of cells bearing activated 
oncogenes by apoptosis may represent the primary means by which such mutant cells are 
continually culled from the body’s tissues.” 
Radiation-induced stimulation of the immune system provides additional protection against 
deleterious stochastic radiobiological effects (Anderson and Lefkovits 1979; Makinodan and 
James 1990; Liu 1998, 2003, 2004; James and Makinodan 1988; Shen et al. 1996, 1997; 
Hashimoto et al. 1999; Takahashi et al. 2000; Matsubara et al. 2000; Kojima et al. 2002; Liu 
et al. 1994a,b; Sakai et al. 2003, 2006; Tubiana 2005; Tubiana et al. 2005). Immunosurveillance 
systems can eliminate clones of transformed cells as seen in tumor cell transplants.  
2.5 Radiation Adaptive Response/Hormesis, a Protective Bystander Effect 
The above system of biological protection relates to radiation adaptive response. Classical 
two-dose, adaptive-response studies have involved administering a small adapting dose that 
after a time delay is followed by a larger test dose (Wolff 1996). Deleterious biological effects 
(usually expressed as a frequency) obtained are then compared to those observed after only 
administering the test dose. A reduced frequency of observed stochastic biological effects with 
the combined exposure is then interpreted to represent adaptation caused by the first dose. The 
first dose activates one or more components of the system of protection discussed in the 
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preceding section. For the two-dose adaptive response study design, it is clear that a low-dose-
stimulated increased DNA repair capacity (a contribution to adaptation) likely plays a major role 
in the indicated reduction in the frequency of stochastic effects (Wolff 1996; Wolff et al. 1988; 
Mitchel 2004). The PAM process is also considered to play an important role in the indicated 
adaptive response. The indicated repair enhancement only occurs after a significant time delay 
and appears to require a threshold dose (Rothkamm and Löbrich 2003). However, cells with 
spontaneous and radiation-induced genomic instability (e.g., precancerous cells) can be 
eliminated via the PAM process, including cells that develop genomic instability as result of 
misrepair of DNA damage.  
Azzam et al. (1996) and Redpath et al. (2001) introduced a novel experimental single-
dose adaptive response study protocol whereby only the small adapting dose is administered. 
The yield of biological effects (neoplastic transformation in vitro to precancerous cells) was then 
compared to the spontaneous frequency for unirradiated cells. To the surprise of many, the 
adapting dose protected against spontaneous neoplastic transformation (adapted protection), 
yielding a decrease (rather than an increase) in the transformation frequency to below the 
spontaneous level. Others (Hooker et al. 2004; Day et al. 2006, 2007) also reported induced 
adapted protection for inversion mutation induction in spleen of pKZ1 mice exposed in vivo to 
low doses of 250-kVp X-rays. Because the single-dose form of protection can occur at low-LET 
radiation doses for which the vast majority of the target cell population receives no radiation hits, 
it is considered to be a protective bystander effect (Scott 2004a). These effects appear to be 
associated with low-LET radiation or combined exposure to low- and high-LET radiation but not 
with only high-LET alpha radiation (Scott 2004a, 2007a-b; Scott et al. 2003). This has an 
important implication for cleaning up environmental contamination caused by radionuclides 
released from DOE sites and other activities. Not only does potential harm from radiation need 
to be considered but also potential radiation-induced protection from harm (i.e., adaptive 
response, a benefit). 
Low-dose-radiation adaptive response/hormesis is a manifestation of radiation ANP. Low 
doses and dose rates of sparsely ionizing radiations (X-rays, gamma ray, and beta radiation) 
have been found to: 
• Protect against chromosomal damage (Azzam et al. 1996). 
• Protect against high-radiation-dose-induced mutations if given before or after the high 
dose (Day et al. 2006, 2007). 
• Eliminate precancerous (neoplastically transformed) cells (Redpath et al. 2001). 
• Prevent chemically induced cancer (Sakai et al. 2003). 
• Stimulate increased immune system functioning (Liu 2007). 
• Suppress alpha-radiation-induced cancer (Tokarskaya et al. 1997a,b,c; Sanders 
2007). 
• Suppress metastasis of existing cancer (Sakamoto et al. 1997; Sakamoto 2004). 
• Protect against diseases other than cancer (Sakai et al. 2006). 
2.6 Environmental Plutonium 
Plutonium (Pu) has the atomic number 94 and was discovered in 1941 by Glen Seaborg 
(Nobel Laureate), Arthur Wahl, and Joseph Kennedy, a group of chemist at Berkeley. In the 
winter of 1941, they bombarded uranium oxide with 16-Mev deuterons from the Berkeley 
cyclotron. They then chemically identified the isotope neptunium-239 (238Np), which decayed by 
beta emission to an isotope of element 94 (Pu) that then emitted alpha particles. With the 
advent of the nuclear arms race in the 1950s, atmospheric nuclear tests were conducted 
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worldwide. During the 1960s, ownership of radioactive materials for energy production (e.g., 
nuclear power) became common. As a result, the levels of man-made Pu increased and 
continue to increase today. This has lead to workplace and environmental exposures of humans 
to Pu. 
Our project has mainly focused on evaluating Pu toxicity to humans. Throughout the 
remainder of this report, the notation PuO2 is used for Pu found in weapons-grade (WG) Pu and 
in soil when in dioxide form. The notation 239PuO2 is specific for the dioxides of the isotope Pu-
239. The notation 239,240PuO2 refers to dioxides of mixtures of Pu-239 and Pu-240. 
The element Pu is largely a human-made hazard produced in association with nuclear 
weapons and is contained in soils around the globe, partly as a result of atmospheric nuclear 
testing. Table 1 presents information about Pu inventories (kCi) in soil in the Northern and 
Southern Hemispheres arising from both nuclear weapons detonations and from SNAP devices, 
based on 1970 measurements. Higher inventories of 239,240Pu from nuclear detonations were 
found in the Northern Hemisphere. 
Table 1.  Estimated fallout of Pu inventories (kCi) in soils around the globea 
Location Weapons 239,240Pu Weapons 238Pu SNAP 238Pu 
Northern Hemisphere 253 ± 33 6.1 ± 0.8 3.1 ± 0.8 
Southern Hemisphere 67 ± 14 1.6 ± 0.3 10.3 ± 2.1 
Total 320 ± 36 7.7 ± 0.9 13.4 ± 2.2 
aBased on measurements of Pu from numerous locations (Holleman et al. 1987). 
2.7 Main Isotopes of Pu 
A typical, large nuclear power reactor creates about 230 kilograms of Pu per year. The 
main isotopes are: 
• 238Pu (alpha emitter), half-life 88 years; 
• 239Pu (alpha emitter), fissile, half-life 24,000 years; 
• 240Pu (alpha emitter), fertile, half-life 6,500 years;  
• 241Pu (beta emitter), fissile, half-life 14 years; and 
• 242Pu (alpha emitter), half-life 37,600 years. 
Alpha particles from the Pu isotopes 238Pu, 239Pu, 240Pu, or 242Pu can harm humans only 
when taken inside the body though inhalation, ingestion, or a wound. The beta emitter 241Pu 
emits low energy beta particles (maximum energy = 21 keV) and is therefore mainly a concern 
when inhaled or ingested. Controversial issues have arisen related to the concentrations of the 
indicated Pu isotopes, along with 241Am (Americium-241, also an alpha emitter), that have 
remained in soil at the Rocky Flats Environmental Technology Site (herein called Rocky Flats) 
after site cleanup. Cleanup of such sites is risk driven, and risk of harm from radiation is 
normally evaluated based on the LNT model. Research results generated in this project and 
discussed in this report bring into question the validity of the LNT risk model for combined 
exposure of adults to alpha, beta, and gamma radiation or for exposure to low doses or low 
doses rates of sparsely ionizing radiation. The LNT model, however, may apply in rare 
circumstances where one is exposed only to high-LET alpha radiation (Scott and Di Palma 
2006) or low-energy (high-LET) neutrons (Rithidech and Scott 2007). 
 12 
Table 2 presents the constituents of WG Pu and their specific activities along with the 
relative radioactivity content (percent of total radioactivity) they represent with respect to the 
total mixture. 
Table 2.  Radionuclide-specific activities for WG Pu and relative radioactivity 
content for key alpha-emitting components (Scott and Peterson 2003). 
Radionuclidea Activity (Bq/g-mix) Relative Radioactivity Content (%) 
238Pu 1.85 x 108 6.57 
239Pu 2.13 x 109 75.69 
240Pu 4.77 x 108 16.95 
241Am 2.22 x 107 0.79 
Total 2.814 x 109 100.00 
aRadionuclides not listed contribute little to total radiation dose. 
3. Methods and Results from Epidemiological Studies of 239Pu-Associated Lung 
Cancer among Mayak Production Association Workers 
Only previously developed dosimetry and medical information were used in our studies of 
lung and liver cancer among Mayak Production Association (PA) workers. Medical 
examinations, interviews with patients, autopsy and biopsy protocols discussed here refer to 
work previously carried out by Russian physicians and scientists prior to initiating our 
epidemiological studies. 
The Southern Urals Biophysics Institute (SUBI) assures that it complied with U.S. DOE 
regulations for protection of human research subjects (CFR 1-1-97) and the Russian Federation 
Law of Public Health Protection (Russian Federation 1993). In addition, the Western Institutional 
Review Board/Western International Review Board granted the project in which these studies 
(lung and liver cancer) were undertaken an exempt status. 
To improve on cancer risk estimate for inhalation exposure of humans to environmental or 
workplace Pu isotopes, we conducted epidemiological studies of lung and liver cancers among 
Mayak PA workers (Tokarskaya et al. 2002, 2006).  
3.1 Lung Cancer Cohort Characteristics 
This was a nested, case-control study based on a population comprised of tens of 
thousands of humans exposed over years to alpha (from inhaled 239Pu) plus gamma radiation 
(from external sources in the workplace). Our cohort comprised 4,390 (77% male) adult 
workers. The first criteria considered for inclusion in the cohort was that the Mayak PA worker 
started work between 1948 and 1970 (48% started work between 1948 and 1959) and that the 
worker was monitored for both external gamma-ray exposures and for body burdens of 239Pu. 
The other criteria were that detailed information was available on the worker’s smoking history 
and standard medical documentation was available.  
The main factor associated with lung cancer induction among Mayak PA workers was 
previously identified to be ionizing radiation (Tokarskaya et al. 1995): high-dose external gamma 
rays and alpha radiation from inhaled 239Pu (as inferred from internal Pu body burdens). During 
the first years of Mayak Pa operation, some workers were exposed to external gamma radiation 
that was significantly higher than permissible levels, i.e., > 50 mSv/y. The higher than 
permissible whole-body gamma-ray doses occurred between 1949 and 1957, and there was a 
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significant inhalation risk for airborne 239Pu, with intakes possibly much higher than permissible 
(>1.48 kBq body burden) before the special respirator, "Lepestok," was adopted in 1957. From 
the 1960s, the whole-body gamma-ray exposure did not exceed the permissible level.  
3.2 Dosimetry for Cancer Studies for Mayak PA Workers 
Ionizing radiation (external gamma radiation and alpha radiation from inhaled 239Pu 
aerosols) was the main occupational hazard. The Mayak Dosimetry Monitoring Service 
registered exposures to external gamma rays by using individual film badges (Vasilenko et al. 
2000). 
During the first years of operation (1948–1952), the estimated annual total-body, gamma 
radiation doses (Dγ) in some instances exceeded 1.0 Gy (maximum individual annual dose, 8.0 
Gy). In this period, dose monitoring was carried out daily. During 1953–1955, the estimated 
maximum annual doses decreased to 1.0 Gy, and doses were monitored weekly. After 1968, 
individual annual total-body, gamma-ray doses did not exceed 50 mGy (corresponds to 50 mSv, 
the permissible level) for most workers. Film badge changes and registrations were performed 
monthly. Initially, the measurement error was approximately 60% (1948–1953); after 1985, it 
was approximately 30% due to improved technology. The thermoluminescent method has been 
used since 1988.  
The SUBI Laboratory of Internal Dosimetry staff estimated a 239Pu body burden based on 
spontaneous excretion of 239Pu in urine (Khokhryakov et al. 1998a, 2000a,b). A systematic 
excreta-based program for monitoring workers’ Pu exposures started in 1970. This program 
involves direct measurement of Pu in large urine samples. The estimates of 239Pu body burden 
and alpha radiation absorbed dose (Dα)  to select organs are based on a biokinetic model that 
uses information on the exposure history and transportability of Pu within the body as inputs into 
models for lung clearance (ICRP 1979; Suslova et al. 2002; Khokhryakov et al. 1995) and 
systemic plutonium excretion (Khokhryakov et al. 2004). Transportability of the 239Pu aerosols at 
different work locations was determined using dialysis methods (Khokhryakov et al. 1998b). 
The urine bioassay is based on the radiochemical technique of the double-phosphate 
precipitation of 239Pu. The error did not exceed 30%; the detection limit was 0.26 kBq (Russian 
Federation 1993). The 239Pu body burden and Dα were extrapolated for the period of interest 
using a retention function based on the indicated biokinetic model. The error in Dα may be 
higher than 30% because additional sources of error contribute to alpha-radiation doses (e.g., 
statistical and systematic error associated with the biokinetic model used to obtain doses) 
(Krahenbuhl et al. 2005). The risk of exceeding the permissible level for inhaled airborne 239Pu 
remained high until a special respirator, “Lepestok,” was introduced in 1957. 
Both Dα and Dγ were estimated for each case and its control for the period from initial 
exposure up to the date of cancer diagnosis. Lagged doses (based on lag = 10 years) were 
used for characterizing dose responses for alpha and gamma irradiation. This may have 
introduced a systematic error favoring an LNT-type response over a threshold-type or hormetic 
response (Appendix B and Section 5.4). 
3.3 Cigarette Smoking History 
Prior to our study, data on the PA workers’ smoking history were acquired during face-to-
face interviews conducted via a standard method employed by medical personal at the SUBI 
(then FIB-1). The smoking index (SI) (a product of the number of years of smoking and the 
number of cigarettes smoked daily) was used as an integral (cumulative) index. Most smokers 
used "papiros" (cigarettes without filters) that were characterized by high tar and heavy metal 
contents. 
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The SIs ranged from 0 to 2000 [(cigarettes/day)*years]. The cigarette pack numbers 
ranged from one-quarter up to two packs per day. The duration of smoking ranged from several 
months to 45 years. 
Cigarette smoking started before employment at the Mayak PA and continued at roughly a 
fixed level. At the time of employment, the SI was approximately 200. About 20 years of 
smoking were required to reach an SI of about 500. For an SI in excess of 900, more than 35 
years of smoking were required. 
3.4 Other Exposures Considered 
Individuals who prior to employment at the Mayak PA worked at least 6 months at such 
facilities as a petroleum-chemical plant, a chemical plant that produced acids, explosives, 
stains, fertilizers, nonferrous metallurgy, or ferrous metallurgy were considered to have prior 
contact with chemicals. 
3.5 Medical Monitoring of Mayak PA Workers 
Early medical monitoring included a provisional examination (before starting work in a 
radiation area) and repeated prophylactic examinations (4 to 6 times/y) after first contact with 
workplace radiation. From 1960, annual examinations (that involved supportive therapy, 
neurology, blood analysis, and X-ray examination) were carried out. Periodically (once in 3 – 5 
years), a large number of workers were examined in the clinic (located in the Radiation 
Medicine Department of the SUBI) by modern functional and other diagnostic methods. 
3.6 Lung Cancer Cases and Associated Controls 
The main group in the present study consisted of all lung cancer cases from 1966 to 1991 
and were verified by morphological investigation among the staff that assembled the above-
described cohort. There were 162 (148 men and 14 women) lung cancer cases. 
The lung cancer cases were investigated in the Pathological Anatomy Laboratory of the 
SUBI hospital. Routine autopsy and histological methods were used: fixation in 10% formalin, 
embedding in paraffin, and staining with hematoxylin and eosin. When judged necessary, 
Schiff’s periodic acid and mucicarmine were used as stains. 
Routine optic microscope procedures were used. Histology was classified in accordance 
with the World Health Organization (WHO) classification scheme (WHO 1982). Controversial 
cases were evaluated by two or three pathologists. Surgical cases (23% of material) were 
evaluated in the pathological anatomy laboratories of special oncological clinics. 
For the 162 workers who had lung cancer and formed the main group, matched controls 
(persons without lung cancer) were assigned. Each case was matched to two controls (1:2 ratio) 
for both men and women (total 324 controls). The matching was based on five factors: sex, year 
of birth (± 5 years), year work began (± 2 years), profession, and workplace (plant, sector, etc.). 
Information about radiation contact, smoking history, and lung diseases was obtained 
after completing both the main and control groups and did not influence the control group 
matching. Matching on the five indicated factors limited the possible control selections for each 
lung cancer case to about three to five persons. This is why for each cancer case, two 
noncancer controls were selected that closely matched the lung cancer case for all five 
indicated factors. In some instances, it was not possible to match the profession exactly, and a 
different profession considered similar was therefore selected. The priority of the factors was as 
follows: sex, plant, year work began, birth date, and profession. Matching on profession, year 
work began, and workplace allowed controlling for possible other important industrial factors not 
considered. 
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3.7 Statistical Methods for Lung Cancer Incident Assessment 
We investigated pair-wise interactions (additive, multiplicative, etc.) based the three 
uncorrelated factors, 239Pu body burden, gamma-ray dose to lung, and cigarette  SI, using the 
odds ratio (OR) approach. The OR was evaluated for individual factors, i.e., A (ORA) and factor 
B (ORB) and for their combination (ORAB). Here subscripts A and B represent the factors being 
considered. The OR was also used to estimate RR.  
Previously we evaluated the OR using the following equation for individual factors or for 
their combination (Tokarskaya et al. 1997c): 
)(
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where m is the number of persons with lung cancer, and (n – m) is the number of persons 
without lung cancer. The subscript I represents the exposed contingent, while the subscript II 
represents the unexposed contingent (i.e., not exposed to the factor or factors of interest).  
In conducting our study, we have instead estimated the OR based on the ratio of 
discordant pairs of type I (DisI) and type II (DisII) (Breslow and Day 1980). Thus, 
OR = DisI/DisII. 
Discordant pairs of type I occur when the case (with cancer) has the exposure, and the 
matched control (without cancer) has no exposure. Discordant pairs of type II represent the 
situation where the case has no exposure, and the control has the exposure. The number of 
concordant pairs (where both the case and control have been exposed or both have not been 
exposed) does not influence the calculation.  
We evaluated the OR for different levels of a given factor. The groupings were made in 
the following way: 
Group 1: High level of factor A and low level of factor B. 
Group 2: Low level of factor A and high level of factor B. 
Group 3: High levels of both factors. 
Group 0: Low levels of both factors to which the other three groups were compared 
(i.e., group was taken as the uninfluenced reference group).  
A statistical characterization of the association between factors was initially evaluated 
based on the comparison of the OR of three groups that had: 
1. A high level of factor A only, 
2. A high level of factor B only, or 
3. High levels of both factors (AB). 
For this grouping, the testing criteria were based on the following: 
Additive effect of factors A and B, ORAB = ORA + ORB – 1;  (1) 
Multiplicative effect of factors A and B, ORAB = ORA ⋅ ORB.  (2) 
A pooled analysis (unconditional logistic regression) was used for preliminary 
characterization of the disease distribution according to the dose levels, but not for interaction 
characterization. For interaction characterization, conditional logistic regression was used. 
Evaluation of homogeneity in OR was based on the McNemar’s relationship (Breslow and Day 
1980) specifically designed for matched data.  
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The homogeneity between discordant pairs was assessed via the χ2 statistic (Breslow and 
Day 1980) whereby  
 χ2=
DisIIDisI
DisIIDisI
+
−− 2)1(
. (3) 
Corresponding calculations were also carried out based on the Mantel-Haenzel method (Fleiss 
1981) but are not reported here as results were similar to results obtained with the above 
equation.  
RR was estimated from OR. Pair-wise comparisons between factor-specific RRs were 
made to test the homogeneity of RR between factors A, B, and the combination AB. To carry 
out these evaluations, 2 x 2 contingency tables were created for which the usual corrected χ2 
(Breslow and Day 1980) was calculated for pair-wise comparisons (A to AB and B to AB). The 
observation of homogeneity was interpreted as an indication of a possible additive effect. The 
absence of homogeneity was interpreted as an indication of a possible interactive effect (sub-
additive, multiplicative, supra-multiplicative, etc.). 
To refine the characterization of interactions between factors A and B, a second approach 
was used whereby confidence intervals for the expected ORAB under the additive and 
multiplicative models were generated via Monte Carlo calculations (10,000 realizations) 
assuming a normal distribution (Breslow and Day 1980) for the variable  
 Prob = OR/(OR+1), (4) 
with mean Probj for a given factor assignment (i.e., j = A, B), where 
 Probj = ORj/(ORj+1). (5) 
The variance (Var) for Prob for a given factor assignment was evaluated as follows (Breslow 
and Day 1980): 
 Var{Prob} = [Probj(1-Probj)/(DisI + DisII)]. (6) 
Fifth and 95th percentile values for the Monte Carlo-generated distribution for ORAB were 
evaluated using Crystal Ball (1996) under both the additive and multiplicative models based on 
Prob having the indicated normal distribution for individual factors A and B with the indicated 
Var (Equation 6). The OR was then used as an estimated RR.  
The ORAB distribution generated was skewed as expected. In some cases, negative 
values were obtained because of using the normal distribution for Prob. The Monte Carlo-
generated percentiles were then compared with observed values for ORAB to evaluate whether 
additive, multiplicative, or other associations were implicated by the data.  
Criteria used for evaluating interactions were as follows: 
• Sub-additive effect: If the observed ORAB for the combined exposure to both factors A 
and B was less than the fifth percentile value of the Monte Carlo-generated ORAB 
distribution under the additive model, then the data were judged consistent with a 
sub-additive effect of the combined exposure. 
• Additive effect: If the observed ORAB for the combined exposure to both factors A and 
B fell between the fifth and 95th percentile values of the Monte Carlo-generated 
distribution under the additive model and the fifth percentile under the multiplicative 
model is greater than the 95th percentile under the additive model, then the data were 
judged consistent with an additive effect of the combined exposure. 
• Intermediate effect: If the ORAB for the combined exposure to both factors A and B 
was greater than the 95th percentile value of the Monte Carlo-generated distribution 
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under the additive model but less than the fifth percentile value under the 
multiplicative model, then the data were judged consistent with an intermediate effect 
(i.e., between additive and multiplicative) of the factors.  
• Multiplicative effect: If the observed ORAB for the combined exposure to both factors A 
and B was greater than the 95th percentile value for the Monte Carlo-generated 
distribution based on the additive model but between the fifth and 95th percentile for 
the multiplicative model, then data were judged consistent with a multiplicative effect 
of the factors. 
• Supra-multiplicative effect: If the observed ORAB for the combined exposure to both 
factors A and B was greater than the Monte Carlo-generated 95th percentiles under 
both the additive and multiplicative models, then the data were judged consistent with 
a supra-multiplicative effect of the factors. 
Although the above criteria are somewhat subjective and overly conservative, they are 
based on reasonable distribution-related considerations under the additive and multiplicative 
models. 
Interactions between smoking and radiation were evaluated for middle (SI = 200 to 900) 
and high (SI = 901 to 2000) smoking levels. Only high levels of radiation were considered 
(Gamma ray dose > 2 Gy; 239Pu body burdens > 2.3 kBq) in interaction evaluations. 
3.8 Results Obtained for Lung Cancer Occurrences among Mayak PA Workers 
With our multivariate analysis of lung cancer occurrence among Mayak PA workers, we 
investigated the pair-wise interactions of previously identified three main etiological factors. 
These three factors are as follows: (1) body burden of 239Pu, an influence on absorbed alpha-
radiation dose; (2) cumulative, absorbed external gamma-radiation dose to the total body; and 
(3) level of cigarette smoking as indicated by  the SI, which represents the number of cigarettes 
smoked per day times years smoking.  
As already indicated, the Mayak PA workers were exposed by inhalation to both soluble 
and insoluble forms of 239Pu. Based on using a cohort of 4,390 persons (77% male), our nested, 
case-control study of lung cancer induction was carried out using 486 matched cases and 
controls. As previously indicated, each case was matched to two controls. Matching was based 
on five factors: sex, workplace (plant), year work began, year of birth, and profession. Three 
levels of smoking were considered: low (SI = 1 to 499), used as a reference level; middle (SI = 
500 to 900); and high (SI = 901 to 2000).  
For lung cancer induction, a supra-multiplicative effect was demonstrated for high, 
external gamma-ray doses (> 2.0 Gy) plus high 239Pu intakes (body burden > 2.3 kBq). This 
observation is consistent with the hypothesis of curvilinear dose-response relationships for lung 
cancer induction by high- and low-LET radiations. The interaction between radiation (external 
gamma rays or 239Pu body burden) and cigarette smoke was found to depend on the smoking 
level. For the middle level of smoking in combination with gamma radiation (> 2.0 Gy) or 239Pu 
body burden (> 2.3 kBq), results were consistent with additive effects. However, for the high 
level of smoking in combination with gamma radiation (> 2.0 Gy) or 239Pu body burden (> 2.3 
kBq), results were consistent with the occurrence of multiplicative effects. These results indicate 
that low-dose risk estimates for radiation-induced lung cancer derived without adjusting for the 
influence of cigarette smoking could be greatly overestimated. Further, such systematic error 
may considerably distort the shape of the risk vs. dose curve and could possibly obscure the 
presence of a dose threshold for radiation-induced lung cancer. 
Our study design used internal controls and dose groups comprised of widely varying 
doses so that we could not efficiently test for radiation adaptive response/hormesis at low doses 
(see Section 5.4). However, a previous publication not using discordant and concordant pairs 
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indicated a rather strong adaptive response (hormesis) after low doses of chronically delivered 
alpha plus gamma radiation doses (Tokarskaya et al. 1995, 1997c). 
We also conducted a study using published Mayak PA worker data from a cohort study 
design with external controls based on Russian national statistics. The indicated data 
demonstrated a dramatic adaptive response (protection against lung cancer occurrence) and is 
discussed in Section 5 along with numerous data on protective effects of low doses and dose 
rates of ionizing radiation. 
4. Methods and Results from Epidemiological Studies of 239Pu-Associated Liver 
Cancer Among Mayak Production Association Workers 
This Mayak-worker-based study focused on evaluating possible associations between 
malignant liver cancers and chronic alpha irradiation, chronic gamma irradiation, and 
nonradiation risk factors (alcohol consumption, smoking, viral hepatitis, chemical exposure, and 
chronic digestive diseases). This was the first multivariate study related to liver cancer among 
Mayak PA workers (Tokarskaya et al. 2006). Detail of the study design and key findings follow 
below. 
4.1 Liver Cancer Cohort Characteristics  
The study included 44 Mayak PA workers with morphologically confirmed (i.e., by 
histological studies) malignant liver tumors that were diagnosed during 1972 – 1999. These 
cases made up the “case” group. Cases of liver cancer (approximately 20 workers) diagnosed 
without any morphological confirmation, i.e., diagnosis based on death certificates, were not 
included in our study. The liver is one of the main sites for metastasis of malignant tumors 
(Tokarskaya et al. 2006). Thus, one cannot exclude the possibility that some liver cancer cases 
without morphological confirmation may represent metastases to the liver of an undetected 
primary tumor.  
The “control” group consisted of 111 Mayak PA workers, who had no known liver cancers. 
The control group included workers from the same Mayak PA plants as the case group and was 
matched by sex, year of birth ± 5 years, year of starting work at the Mayak PA ± 2 years, and 
work assignment. The case-control ratio was 1:2 or 1:4. 
4.2 Dosimetry 
Dosimetry is explained in Section 3.2. 
4.3 Alcohol Consumption Categories and Smoking Levels 
The alcohol consumption was characterized using three disjoint levels: 
a. Rare drinker: less than 40 mL ethanol per week. 
b. Moderate drinker: about 200 mL ethanol per week. 
c. Heavy drinker: much more than 200 mL ethanol per week. 
Russian medical staff interviewed patients directly during visits to the SUBI Clinic to obtain 
the detailed smoking history (age started smoking, duration, number of cigarettes). The  SI 
(product of daily smoked cigarettes and years of smoking) was used as a cumulative index.  
4.4 Other Exposures Considered 
Individuals who prior to employment at the Mayak PA worked at least 6 months at such 
facilities as a petroleum-chemical plant, a chemical plant that produced acids, explosives, 
stains, fertilizers, nonferrous metallurgy, or ferrous metallurgy were considered to have prior 
contact with chemicals. 
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4.5 Medical Monitoring 
Medical follow-up of the case and control groups was the same as for all nuclear workers 
at the Mayak PA. The medical follow-up included an initial examination followed by annual 
ambulatory examinations (therapeutic, neurological, and blood analyses). Occasionally (once 
every 3−5 years), nuclear workers were examined in the Clinical Department of the SUBI. 
Information on digestive diseases, viral hepatitis, prior exposure to chemical agents, and 
alcohol consumption was obtained from medical records (ambulatory cards, case histories). The 
information on individual alcohol consumption was verified in the Narcological Service Archive. 
The Virology Laboratory provided information on markers of viral hepatitis B and C. 
However, viral hepatic marker information was available for < 10% of the studied individuals. 
For individuals without viral hepatitis marker information, we evaluated the occurrence of viral 
hepatitis based on medical records. This diagnosis was therefore made based on the clinical 
data without any virological analysis. Most of such cases with hepatitis were registered during 
1940 – 1960. Hepatitis A, which was not found to be associated with liver cancer, was prevalent 
in Russia during that period. 
Data on liver tumor morphology (histological types) are based on autopsy or biopsy 
protocols established during 1972 – 1999. All cases were studied at the same pathology 
laboratory using routine autopsy and histological methods (Tokarskaya et al. 1995). 
4.6 Auxiliary Controls 
In addition to the control group used for case-control studies, another group (comparison 
group) was used for comparison when evaluating the frequency distribution (i.e., cancer 
spectrum) of different types of liver cancer among Mayak PA workers. The comparison group 
comprised cases (n = 28) with malignant liver tumors diagnosed during 1972 – 1999 among 
Ozyorsk citizens who had never worked with radiation. Their ages and gender corresponded to 
the cancer cases among workers (those born during 1910 – 1946).  
4.7 Statistical Methods for Liver Cancer Incidence Assessment 
The case and control groups were compared using both single independent-variable and 
multivariate analyses. The “t” criterion was used for comparing sample averages. The “χ2” 
criterion was used for comparing frequency ratios in univariate analyses. Nonparametric 
statistics (Man-Whitney U-test and Kolmogorov-Smirnov test) were used to account for the 
possibly skewed distributions (Handbook of Applicable Mathematics 1989). 
Our main research objective was to study possible associations between several risk factors 
and the occurrence of liver tumors using multivariate methods. Two analytical approaches were 
used: (1) quantitative variables were grouped (i.e., categorized) and unconditional logistic 
regression was employed to obtain OR as an estimate of RR; (2) quantitative continuous variables 
were not grouped and conditional logistic regression analysis for matched case-control studies 
(SAS PHREG procedure) was employed to obtain the hazard ratio (HR) as an estimate of RR. 
Multivariate, conditional regression implemented with the PHREG routine (SAS Institute 2001) 
was used to estimate HR based on the Cox model. Using SAS, the PHREG routine can be 
implemented in a mode that is equivalent to conditional logistic regression.  
Analyses were carried out separately for each type of liver cancer considered, as well as 
for all three types of liver cancers combined. Multiple logistic regression (based on the 
maximum likelihood criterion) was used in our multivariate analyses involving grouped data. The 
logistic regression procedure facilitated adjusting for confounding factors when calculating OR 
(Breslow and Day 1980). The quantitative risk factors considered included the following: 239Pu 
body burden (or the corresponding absorbed alpha-radiation dose to the target tissue), the 
external gamma-ray dose to the total body, and the SI. Although these variables are continuous, 
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dose groups (categorized representation) were used for estimating crude odds ratios (ORcr), 
adjusted odds ratios (ORad) in our multivariate analyses based on logistic regression and 
attributable risk (AR). Some additional nominal variables (e.g., alcohol abuse, chemical 
exposure) were represented as a binary variable.  
Attributable risk was calculated for specific risk factors and specific liver cancer types 
using methods described in Fleiss (1981) and Rothman (1996). With the multivariate conditional 
regression analyses, our focus was on identifying significant contributions of specific risk factors 
(e.g., alpha-radiation dose, gamma-radiation dose, alcohol abuse) to the overall regression. For 
the continuous variable analyses, estimates of individual radiation doses and individual SI were 
used. Covariates included were Dα  (linear [L] or quadratic [Q] forms), Dγ (L forms), and alcohol 
misuse (binary variable) (yes [1], no [0]). Using ungrouped doses avoids a systematic error 
linked to implementation of nonlinear models (i.e., modeling with Q forms) with dose groups.  
A p-value ≤ 0.05 was considered significant in all statistical tests for associations. Also, p-
values in the range 0.05 < p < 0.1 were considered marginally significant and were interpreted 
as representing a weak association (Tokarskaya et al. 2006). All statistical calculations were 
carried out using SAS Version 8.02 (SAS 2001).  
4.8 Results Obtained for Liver Cancer Occurrences among Mayak PA Workers 
As indicated, the study was performed using the nested, case-control approach and 
included 44 cases of malignant liver tumors diagnosed from 1972 to 1999 and 111 matched 
controls. The ORad was evaluated relative to a group of workers with liver dose Dα < 2.0 Gy 
(Tokarskaya et al. 2006). Dose estimates > 2.0 Gy (corresponding 239Pu body burden estimates 
> 20.4 kBq) were significantly associated (p < 0.003) with the occurrence of hemangiosarcomas 
(HAS) but only marginal significance (0.05 < p < 0.1) was found for hepatocellular cancers 
(HCC). The ORad for HAS was 41.7 (95% confidence interval [CI]: 4.6, 333) for a group with Dα 
in the range > 2.0 – 5.0 Gy and was 62.5 (7.4, 500) for a group with Dα > 5.0 – 16.9 Gy. The AR 
was calculated as 82%. For HCC, the ORad was estimated as 8.4 (0.8, 85.3; p < 0.07) for a 
group with Dα in the range > 2.0 − 9.3 Gy. For the indicated group, the AR was 14%. An 
association with high, external Dγ to the total body was revealed for both HCC and for combined 
liver cancers when dose was treated as a continuous variable. However, we found no evidence 
that chronic low doses of gamma rays are associated with liver cancer occurrence. 
Cholangiocarcinoma (CHC) was not associated with either alpha- or gamma-ray exposure. As 
expected, an association between alcohol abuse and HCC was inferred (ORad = 3.3 [1.2, 9]; 
AR = 41%) but not for CHC or HAS. 
The study designed used involved averaging odds of cancer (relative to no cancer) over 
wide dose intervals and then using the interval specific average odds to obtain the OR as is 
done in most epidemiological studies (Scott 2007d). This, along with the use of internal controls 
(including Mayak PA workers also exposed to low-level radiation), made it difficult to test for 
radiation adaptive responses associated with the gamma-ray component of the total radiation 
dose (Scott and Di Palma 2006; Appendix B). However there is now abundant evidence for low-
dose/low-dose rate radiation-related adaptive response/hormesis for cancer. Some of this 
evidence is presented in Section 5. 
5. Modeling, Experimental, and Epidemiological/Ecological Evidence for Radiation 
Adaptive Response/Hormesis for Lung Cancer 
5.1 Novel HRR Model for Cancer Induction 
It is now known that through evolution, mammalian life forms have developed natural 
cancer preventative processes (chemically and biologically regulated) that are stimulated by low 
doses and dose rates of sparsely ionizing forms of radiation (e.g., X-rays, gamma rays, beta 
particles). Low doses and dose rates of these radiations stimulate protective intercellular and 
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intracellular signaling that lead to ANP (activated natural protection) against cancer and other 
genomic-instability-associated diseases (Scott and Di Palma 2006). The protective signaling 
appears to be a generalized response to mild stresses above an individual-specific threshold 
level.  
Radiation ANP (also called radiation hormesis [Calabrese et al. 2007]) appears to be an 
evolutionary benefit of the interaction of low-level ionizing radiation with mammalian life forms 
on earth. Thus, ANP is evolutionary conserved (Mitchel 2007). High radiation doses and dose 
rates rather than preventing cancer, inhibit the protective processes that suppress cancer (Scott 
and Di Palma 2006). Appendix C discusses biological signaling associated with the PAM 
process which, when stimulated by low dose radiation, removes precancerous and other 
aberrant cells. The important role low-dose radiation-stimulated immune functions play in ANP 
against cancer and other genomic-instability-associated diseases is discussed in a number of 
papers (Liu 1988, 2003, 2004, 2007; Scott and Di Palma 2006). 
Here, the focus is on application of our novel HRR model of lung cancer data for 
protracted exposure to low doses of alpha radiation in combination with very low doses of 
gamma rays to demonstrate the highly efficient prevention of lung cancer by gamma-ray ANP. 
Alpha radiation administered alone is a potent inducer of lung cancer. Small doses (close to 
natural background radiation levels) can cause a significant increased incidence (Lundgren 
et al. 1991; Sanders 2007). However, for combined exposure to low-dose alpha and very-low-
dose gamma rays, the gamma-ray ANP can prevent cancer induction by alpha radiation. The 
level of protection can be quantified using our HRR model (Figure 5) as explained below.  
 
Figure 5.  Hormetic relative risk (HRR) model. Individual-specific threshold doses above 
absolute zero natural background are responsible for ANP and occur in Transition Zone A. The 
dose b is the current natural background dose. Everyone is protected for doses from D* to D** 
(Zone of Maximal Protection). Individual-specific threshold doses for suppression or inhibition of 
some ANP occur between doses D** and D*** (Transition Zone B). Only DNA repair is 
presumed to contribute to protection for doses > D***, and the RR curve intersects the LNT risk 
curve for a range of dose. Reducing doses to below < D* is expected to lead to harm, rather than 
to benefit due to loss of ANP. The LNT curve when extrapolated down to b gives phantom excess 
risk. Sharp bends are artificial and used only to clarify the different dose zones in a clear way. 
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With the current version of our HRR model and for doses above the natural background 
dose b and below, the irradiated population is separated into two dose- and dose-rate 
dependent parts: (1) those that have ANP and (2) those without ANP. For persons with ANP, 
the population average cancer RR is given here by  
 RRANP = (1 – PROFAC)RRLNT (7) 
where RRANP is the RR for persons with ANP (i.e., protected individuals) and RRLNT is the RR for 
persons without ANP and is based on the LNT assumption. Bayesian methods allow evaluating 
the expected proportion of the population that is protected for a given dose and dose rate, and 
radiation combination when formally fitting the model to data (Scott and Di Palma 2006). 
The protection factor (PROFAC) takes on values from 0 to 1 and here accounts for 
prevention of cancer via gamma-ray ANP. A value of PROFAC = 0.25 would indicate that 
cancer would be expected to be prevented in 1 in 4 individuals among those with ANP. For a 
hypothetical population containing 1000 protected  (by low-dose gamma-ray ANP) heavy 
cigarette smokers, if 100 were expected to develop lung cancer because of smoking, then with 
PROFAC = 0.25, 25 of the 100 would be expected to be prevented from developing smoking-
related lung cancer. Thus, not every protected person is expected to escape lung cancer 
occurrence.  
For alpha-radiation-induced lung cancer, RRLNT is evaluated based on: 
 RRLNT = 1 +[ (1-B)/B]KαDα , (8) 
where B is the baseline (spontaneous) cancer incidence, Kα is the presumed always-positive 
slope parameter in the HRR model, and Dα is the alpha radiation dose. Equation 7 is used for 
evaluating cancer RR for combined exposure to low-dose alpha and gamma rays while 
Equation 8 applies to exposure only to alpha radiation (Scott 2007a,d). The PROFAC relates 
only to low-dose gamma rays (or a radiation type of similar interaction characteristics such as X-
rays and beta radiation when used instead of gamma rays). Note that RRLNT in Equation 8 is a 
response surface that depends not only on dose Dα but also on the baseline cancer frequency 
B.  Thus, epidemiological studies using different dose groups with different baselines B for each 
group need to adjust to a common baseline in order to legitimately plot a single dose-response 
curve for RR vs. dose. The HRR model is applied elsewhere (Appendix B) to both animal and 
human data for the RR for lung cancer induction by combined chronic exposure to alpha and 
gamma radiations. Key findings are summarized in Section 5.2. PROFAC estimates for 
preventing different types of cancer derived from numerous epidemiological and ecological 
studies are summarized in Section 5.3. 
5.2 Application of the HRR Model to Lung Cancer Data for Inhalation Exposure to Alpha or 
Alpha Plus Gamma Emitting Radionuclides  
With the HRR model, exposure at low rates over an extended period to low doses of 
gamma rays is predicted to significantly suppress lung cancer induction by alpha radiation. 
However, for high doses of alpha radiation, the ANP-related signaling is presumed to be 
suppressed or overwhelmed by deleterious signaling (Appendix B). Lung cancer RR data and 
HRR-model-generated RR estimates are presented in Figure 6 for humans, dogs, and rats that 
were exposed to both low and high alpha-radiation doses alone or in combination with low-dose 
gamma rays. Lung cancer RR for Wistar rats that inhaled both the alpha emitter 239Pu and the 
gamma emitter ytterbium-169 (169Yb) are indicated by the filled squares and are based on data 
from Sanders (2007). Also shown is the adjusted RR for Wistar rats for inhalation exposure to 
only Pu-239 (filled circles) based on data from Sanders (2007), after adjusting to a baseline of 
95/100,000 (same as for 239Pu + 169Yb-exposed rats). The adjusted RR for Beagle dogs (closed 
triangles) that inhaled the alpha emitter 238Pu in an insoluble form based on data from 
 23 
Muggenburg et al. (1996) after adjusting to a baseline of 95/100,000 is also presented. 
Logarithmic scales are used on both axes. 
 
Figure 6.  Lung cancer RR data for Wistar rats exposed to low and high alpha radiation doses alone 
(filled circles) or in combination with low-dose gamma rays (filled squares) from a 169Yb tag. Lung 
cancer data for beagle dogs exposed to very high alpha and low-dose gamma radiation (filled 
triangles). The lower smooth curve is based on fitting Equation 7 to human data (Mayak PA workers) 
using Bayesian inference and adjusting for a different baseline. All results in the figure relate to a 
baseline lung cancer incidence of B = 95/100,000. The upper smooth curve was obtained for 
unprotected humans by changing PROFAC = 0.86 (smooth curve for humans) to PROFAC = 0 (i.e., 
no protection; Equation 8). Values for RR = 0 are plotted at RR = 0.01. The zero dose groups for 
which RR = 1 are excluded. The horizontal line is for RR = 1. 
The expected adjusted RR for Mayak PA workers (smooth curve) exposed via inhalation 
to 239Pu in combination with external gamma rays, based on fitting the HRR model to Mayak PA 
worker data from Kokhryakov et al. (1996) using Bayesian methods (Scott and Di Palma 2006) 
and adjusting for a baseline to 95/100,000 is also presented in Figure 6. The study used 
external controls, with a dose-group-specific baseline evaluated, based on Russian national 
statistics. This eliminates the systematic error associated with inclusion of persons receiving 
low-doses in the control group (a problem with most low-dose epidemiological studies). The 
upper dashed cure in Figure 6 is predicted for humans in the absence of the protective low-dose 
gamma rays based on Equation 8 and is in reasonable agreement with the data for Wistar rats 
(filled circles) that received only alpha radiation exposure. The rat and dog data converge at 
high doses where protection is presumed to be inhibited. The high-dose results can be 
presumed to also apply to humans for the indicated baseline. Interestingly, the RR seems to 
approach a plateau at very high doses (> 10,000 mGy), although a logarithmic scale is used 
and disguises large changes in the data. 
For Wistar rats that receive average alpha radiation doses of 56, 190, and 620 mGy to the 
lung in combination with low-dose gamma rays, the expected RR assuming no gamma-ray ANP 
(based on low-dose data for rats exposed only to alpha radiation and Equation 8) was 13, 43, 
and 137, respectively. However, the observed RR values were zero in each case, implication 
PROFAC = 1.0 (Equation 7) for gamma-ray ANP against lung cancer induction. Thus, 100% of 
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lung cancers (alpha-radiation-induced and spontaneous) were apparently prevented! However, 
for alpha radiation doses > 1000 mGy deleterious signaling is implied to predominate, thereby 
inhibiting or overwhelming protective signaling associated with the extended low-rate exposure 
to low doses of gamma rays for the 169Yb tag. For Mayak PA workers chronically exposed to 
alpha and gamma rays over many years the estimated gamma-ray ANP was somewhat less 
(PROFAC = 0.86 ± 0.07). See Appendix B for more detail on the data in Figure 6. 
5.3 Data Showing PROFAC > 0, Based on Radiation Epidemiological/Ecological Studies 
Values of PROFAC significantly > 0 for cancer incidence (or mortality) demonstrate 
cancer prevention. Estimates of PROFAC for a number of irradiated human populations have 
been derived based on cancer mortality and incidence data and are presented in Table 3 (see 
Scott and Di Palma 2006 for additional data). Radiation exposures were presumed to have 
occurred in the Zone of Maximal Protection (i.e., maximal low-LET-radiation ANP) in cases 
where RR or SMR (standardized mortality ratio) was < 1. All indicated PROFAC values were 
significantly > 0 (p < 0.05). PROFAC values range from 0.15 to 0.97. Residing in U.S. states 
with high natural background appears to suppress cancer occurrence (PROFAC = 0 .15). 
PROFAC variation may relate, in part, to different genetic characteristics (e.g., polymorphisms) 
for the different irradiated groups.  
Table 3.  Central estimates of the presumed radiation-hormesis-related protection 
factor (PROFAC) against cancer in humans (Scott and Di Palma 2006). 
Group Effect Radiation Types PROFAC 
Chernobyl accident recovery 
workers 
Cancers Low- plus high-LET 0.13a 
USA, residents of high 
background states 
Cancers Low- plus high-LET 0.15a 
British medical radiologistsb 
after 1955-1979 
Cancers Low- plus high-LET 0.29a 
High residential radon, USA Cancers Low- plus high-LET 0.35a 
Canadian nuclear industry 
workers 
Leukemia Low- plus high-LET 0.68a 
USA DOE facilities workers Leukemia Low- plus high-LET 0.76a 
Russian Mayak plutonium 
facility workers 
Lung cancer Low- plus high-LET 0.86a 
Taiwanese in cobalt-60 
contaminated apartments 
Cancers Low-LET 0.97a 
aPROFAC significantly > 0 (p < 0.05).  
bEvaluated relative to all men in England and Wales. 
The product 100*PROFAC gives the expected number of deaths from cancer avoided due 
to radiation-induced adaptive protection (hormesis) for each 100 cases that would have 
otherwise occurred, when everyone is protected. Thus, for Mayak PA workers, 86 lung cancer 
deaths are expected to have been prevented for each 100 lung cancer deaths that would have 
otherwise occurred in the absence of their chronic exposure to gamma radiation. It was 
assumed that all workers were protected by their extended low-rate exposures to gamma rays. 
The gamma-ray ANP-related PROFAC of 0.86 is a pronounced level of protection against 
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normally occurring harm, including harm associated with cigarette smoking. The results 
presented for Taiwanese living in cobalt-60 contaminated apartments (PROFAC = 0.97) is 
based on controversial data. A lower PROFAC value may actually apply. 
Other ANP-related PROFACs are presented in Table 4, based on data for persons 
residing in a high-level radon spa area in Japan (Mifune et al. 1992). Only the gamma-ray 
component to the radon dose is presumed to be associated with ANP (Scott and Di Palma 
2006). 
Table 4.  Central estimates of high-level, radon-associated PROFACs 
against cancer at different sites in the body based on cancer mortality 
data for persons residing in a high-level radon spa area in Japan  
(Scott and Di Palma 2006) 
PROFAC 
Cancer Site or Type Females Males 
Leukemia 0.47 0.56 
Stomach 0.55 0.60 
Breast 0.74 – 
Lung 0.81 0.53 
Colon/rectum 0.86 0.70 
 
Figure 7 presents PROFAC against breast cancer occurrence in females as a function of 
age at exposure to diagnostic X-rays based on data from Nyström et al. (2002; Scott and Di 
Palma 2006). Female patients received fractionated diagnostic X-ray exposures 
(mammograms) related to breast cancer screening.  
 
Figure 7.  X-ray PROFAC against breast cancer based on data from Nyström et al. (2002). 
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A strong age dependency is implicated in Figure 7 for low-dose-radiation ANP against 
breast cancer in adult females. The PROFAC increases to a plateau as age increases. DNA 
repair fidelity is known to be reduced with increasing age. Thus, the genomic instability burden 
is expected to increase as we age because of reduced DNA repair. However, this increased 
genomic instability burden would be expected to be associated with an increased role of the 
PAM process and immune system stimulation in protecting against genomic-instability-
associated diseases such as cancer. The PAM process involves signaling between normal and 
genomically unstable cells. The higher the concentration of unstable (aberrant) cells the 
stronger the signaling associated with the PAM process is expected to be, once signaling is 
initiated (Scott 2004a). Thus, one would expect the PROFAC to increase as age increases for a 
given genomic-instability-associated disease. The results appear to indicate that the aged 
benefit more from induction of the PAM process and enhanced immunity than do young adults. 
Whether or not the very young will benefit from the PAM process is unclear. Such persons 
without significant burdens of genomically unstable cells may not benefit from the PAM process.  
5.4 Epidemiological Procedures Used that Hide Actual Departures from LNT Risk Functions 
Appendix B presents an in press paper (Scott 2007d) that discusses procedures used in 
epidemiological studies to hide the presence of hormetic responses and thresholds in the dose-
response curve for cancer induction. The epidemiological procedures are summarized below. 
5.4.1 Procedure #1: Dose Lagging 
Some of the actual radiation dose is discarded in many epidemiological studies that 
employ the LNT risk function. This process is called dose lagging. Throwing away dose is 
related to the view that some of the dose must be wasted. However, the notion of there being 
wasted dose and the dose-response curve being of the LNT type is a contradiction as explained 
in Scott and Di Palma (2006) based on more recent research. Throwing away dose can hide 
hormetic-type responses at low doses and thresholds for excess cancer risk. This was not 
realized when we conducted our lung and liver cancer studies related to Mayak PA workers. 
5.4.2 Procedure #2: Eliminating the Hormetic Dose Zone via Averaging over Dose Groups 
In case control studies, dose groups are often comprised of individuals with doses 
spanning a wide range. The statistical procedures used to obtain the OR (usually evaluated 
relative to the lowest dose group that includes exposed and unexposed individuals) essentially 
averages odds of cancer (against no cancer) over the indicated wide dose intervals. The 
averaged odds are then used to obtain the OR that, in turn, is used to estimate RR. As 
demonstrated in Appendix B, this procedure can change an actual hormetic-type, dose-
response curve (with low-dose prevention of cancer) into what appears to be an LNT type curve 
(where any amount of radiation is implicated as being harmful). This was not realized when we 
conducted our lung and liver cancer studies related to Mayak PA workers. 
5.4.3 Procedure #3: Constraining the Slope of the Cancer Risk Dose-Response Curve to 
Always Be Positive 
With this procedure, high-dose data is always included in the analysis to ensure a positive 
slope to the LNT-type dose-response curve. It does not matter if the low-dose data show or 
suggest a reduction in RR to below 1. This is simply ignored (more weight given to the high-
dose data). This leads to ignoring the hormetic implications of the low-dose data. Only the 
positive slope obtained for the dose-response curve is usually presented. The actual data used 
is often not presented so as to effectively hide the low-dose departure from linearity. See 
Appendix B for additional discussion. 
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6. Low-Dose-Radiation ANP Implications for Establishing RSALs 
The cost of cleanup and the associated management costs of Pu and other radionuclide-
contaminated sites, notably sites where processing of large amounts of nuclear materials has 
been done, are estimated to run into hundreds of billions of dollars in the United States alone 
(Makhihani and Gopal 2001). Ensuring the effectiveness of public expenditures in ways that are 
compatible with health and environmental protection for thousands of years is quite challenging. 
The level of cleanup is closely linked to the LNT risk model for cancer induction and the 
associated annual effective doses. Thus, any amount of residual radioactivity in soil, no matter 
how small, is calculated to be associated with an increased cancer risk. Having scientifically 
justifiable reasons for considering thresholds for radiation doses that cause harm could lead to 
greatly reducing the cost of cleaning up radionuclide-contaminated sites. 
We discuss in an in press paper the implications of low-LET-radiation ANP for regulating 
worker and public exposures to ionizing radiation (Scott 2007d; Appendix B). Here, the focus is 
on implications for establishing more realistic RSALs, taking into consideration low-LET-
radiation ANP. RSALs are radionuclide concentrations in soil that when exceeded trigger an 
evaluation, remedial action, and/or management action, given the presence of institutional 
controls. Because of low-LET-radiation ANP, cancer risk after combined exposures to low doses 
of radiation from alpha, beta, and gamma-emitting radionuclides in soil of remediated DOE and 
other sites can be considerably less than would be expected based on the LNT hypothesis, and 
can actually be less than the risk would be in the absence of radiation exposure. However, the 
susceptibility characteristics of the at-risk human population are quite important. Radiation ANP 
considerations for adults would be different from those of children. Thus, for an industrial site 
established in a remediated area, risk considerations would likely relate to adults. However, for 
a family residing at the site (e.g., farming family) children could be at risk for radiation harm.  
Under circumstances of combined exposure to low-LET beta and or gamma rays along 
with alpha radiation from contaminated soils, if the annual absorbed doses are low (up to 10 
mGy of for each type), then for adults residing or working at such a location one would not 
expect any increase in cancer risk; and in fact, if the person is a heavy smoker their risk of 
cancer may be much less than if they received no radiation exposure from the indicated site. 
This points to the need for establishing RSALs based on realistic risk of harm, rather than using 
the default LNT assumption. The regulatory radiation absorbed dose threshold (REGRADT) 
that represent the radiation-specific minimum absorbed radiation dose (for the most sensitive 
person) to a given organ for the loss of ANP (lower end of Transition Zone B in Figure 5) could 
be used to obtained more realistic RSALs. Loss of ANP is equated with harm in that cancer risk 
is expected to increase because of this loss. REGRADTs are introduced in the in press paper 
by B.R. Scott (Appendix B) in connection with regulating worker and public exposures to 
ionizing radiation. 
For a given radionuclide, the soil concentration for the exposure scenario could be 
considered an action level when evaluated at the concentration that corresponds to the 
REGRADT (evaluated as an annual dose), taking into consideration each type of radiation 
associated with the radionuclide and considering the likely low-LET radiation ANP below the 
action level. If RSALj is used to represent the current soil action level for the jth radionuclide 
based on an LNT extrapolation from high-dose data, then for circumstances where gamma- 
and/or beta-emitting radionuclides are present in soil and min{PROFAC} (i.e., the minimum 
PROFAC evaluated over all irradiation organs/tissue of the body) relates to the low-LET 
radiation exposure (low doses and dose rates presumed), then the modified action level: 
 RSALj* = RSALj/(1 - min{PROFAC})  (9) 
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would be a more scientifically justifiable choice than RSALj. As illustrated in Figure 5, RSALj is 
based on phantom excess risk at low doses from radionuclides in soil when ANP occurs. In the 
absence of estimates of min{PROFAC}, a conservative value, e.g., 0.25, could be assigned. A 
similar approach could be used for beta- and gamma-emitting radionuclides. 
If Cj is used to represent RSALj* for each radionuclide j, and cj is the corresponding soil 
concentration for the radionuclide, then the action level for mixtures of radionuclides in soil could 
be evaluated according to the constraint: 
 .1/
1
<∑
=
n
j
jj Cc  (10) 
Exceeding the constraint in Equation 10 would trigger the appropriate evaluation, remedial 
action, and/or management action, given the presence of institutional controls. 
Because ANP appears to decrease with decreasing age, special consideration needs to 
be given to the age when determining appropriate land uses for remediated radionuclide sites. 
In some instances, using land comprised of radionuclide-contaminated soil may be restricted to 
adults who would be expected to have high levels of ANP as compared to children. Thus, the 
contaminated site might be restricted to industrial applications where only adults had access to 
the site, rather than, for example, allowing the site to be used for farming activities by a family 
with children or with children planned. New funded ANP-related research is needed to facilitate 
acceptance of Equation 10 by the general public and government agencies. 
7. Biological Dosimetry for Inhaled PuO2 
We explored the possible use of Mayak PA worker clinical data in biological dosimetry for 
inhaled 239Pu. Our interest was in using the clinical data for Mayak PA workers with estimated 
239Pu body burdens and estimated radiation doses (alpha and gamma) to develop calibration 
relationships that could be used for other individuals with estimated gamma-ray doses (but not 
estimated 239Pu intake) to estimate their 239Pu incorporation and/or their radiation dose to a 
selected organ/tissue.  
Based on exploratory analyses of the clinical data (chromosomal aberrations among 
peripheral blood lymphocytes, respiratory function measurements, and hematological data), 
empirical mathematical models were developed for use in creating calibration curves for 
biological dosimetry for both 239Pu incorporation and alpha radiation dose (where possible). The 
chromosomal aberrations data appeared to be the most reliable, followed by data for peripheral 
lymphocyte depression. Respiratory function, although altered modestly by the combined alpha 
and gamma-ray exposures, was found to be the least reliable for use in biological dosimetry due 
to very large scatter. Our modeling of the respiratory function data is described in a recently 
submitted paper (Belyaeva et al. 2007).  
Here, we briefly summarize results obtained based on chromosomal aberrations among 
peripheral blood lymphocytes. Stable and unstable aberrations were analyzed for a group of 
Mayak PA workers with body-burden estimates of 239Pu in the range of 0 – 11.4 kBq. The dose-
response curve for the average of the total aberrations (or for specific aberrations) was well 
characterized by the empirical nonlinear equation: 
 Y = E{y} =E{ N – N0} = α ln(X). (11) 
Here, the notation “E{y}” represents the expectation value of y. The random variable y = N – N0, 
where the random variable N represents the measured aberrations (stable and unstable) per 
100 cells scored; the random variable N0 represents the corresponding spontaneous aberrations 
per 100 cells scored. Dα is the absorbed alpha-radiation dose to tracheobronchial lymph nodes; 
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Dα,T is a postulated threshold-absorbed alpha-radiation dose for excess aberrations, relative to 
the spontaneous level and conditional on chronic exposure over an extended period to both 
alpha and gamma radiations. The parameter α is the slope of the dose-response curve for Y 
when ln(X) is considered as an independent variable (e.g., X plotted on a logarithmic scale, i.e., 
log base “e”). The normalized dose X is given by 
 X = Dα/Dα,T. (12) 
Values of Y < 0 were not explored but would implicate gamma-ray ANP.  The random variable y 
was modeled as having a normal distribution with mean Y and constant variance σ2.  
Figure 8 shows the calibration curve obtained in terms of Dα based on Equation 11. Data 
points plotted are means, and error bars are ± one standard deviation. Parameter estimates 
obtained were as follows: N0 = 1.3 ± 0.2 per 100 cells, Dα,T = 284 ± 44 mGy, and α = 1.63 ± 0.04 
(has no units). Please note that the existence of a threshold for alpha radiation-induced excess 
aberrations long after initial exposure to 239Pu is more complex than it may first appear. One has 
to consider that the workers whom the data represent were also chronically exposed over years 
to relatively low-rate external gamma rays. The gamma-ray dose was assumed to be protective.  
 
Figure 8.  Absolute threshold, calibration curve (Y vs. ln[X]) based on total chromosomal aberrations 
among 100 peripheral blood lymphocytes from Mayak workers chronically exposed to alpha and 
gamma-ray doses. The curve allows estimation of alpha radiation doses to tracheobronchial lymph 
nodes above a threshold Dα,T = 290 mGy, and relates to years after initial intake of Pu. The curve is 
not expected to apply to early years after initial 239Pu intake. Gamma-ray ANP over years is 
expected to have eliminated many of the aberrant cells induced by alpha radiation during early years 
of employment at the Mayak PA. 
The normalized dose, X, in Equation 11 can also be evaluated based on 239Pu body 
burden (BB) for long-term follow-up. The corresponding threshold is given by BBT (which 
replaces Dα,T in Equation 12). The resultant calibration curve is presented in Figure 9, where 
239Pu BB is in units of kilobecquerels. Model parameter obtained were BBT = 0.4 ±  0.2 kBq and 
α = 2.51 ± 0.29. 
The absence of excess aberrations in Figure 8 below the threshold alpha dose Dα,T = 285 
mGy is rather remarkable given that some workers had significant gamma-ray doses (in addition 
to significant alpha radiations doses), although they were delivered at relatively low rates over 
prolonged periods (Figure 10). The data are therefore quite consistent with repeated occurrence 
of the PAM process and repeated activation of high-fidelity DNA repair (gamma-ray ANP-
Total number of aberrations – Dose Dα to lymph nodes 
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associated) under conditions of extended exposures at very low rates to gamma rays. The 
implications is that gamma-ray ANP eliminated alpha-radiation-induced and possibly also 
spontaneous aberrant lymphocytes from the body. Newly reported in vitro studies with human 
lymphocytes indicate that low-dose, gamma-ray ANP can indeed suppress spontaneous 
aberrant cells (micronucleated cells) (Rithidech and Scott 2007). Table 5 summarizes results 
from Rithidech and Scott (2007). Interestingly, the alpha radiation threshold of 284 mGy 
(tracheobronchial lymph node dose) in Figure 8 is quite consistent with the minimum doses to 
the lung, as shown in Figure 6 where gamma-ray ANP appears to be lost so far as preventing 
the occurrence of lung cancer in rats and dogs.  
 
Figure 9. Absolute threshold calibration curve [Y vs. ln(X)] based on total chromosomal aberrations 
among Mayak workers chronically exposed to alpha and gamma ray doses. Here the 239Pu body 
burden is used for X in Equation 9. The curve allows estimation of the 239Pu body burden for burdens 
above a threshold BBT = 0.4 kBq and relates to years after initial intake of 239Pu.  
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Table 5.  Presence and absence of evidence for low-LET-radiation ANP against aberrant 
(micronucleated) cells among human lymphocytes exposed in vitro to different radiations 
based on data from Rithidech and Scott (2007). 
Radiation Type 
Low-LET Component  
to the  
Radiation Dosea 
Evidence for Suppression  
in Aberrant Cells due to  
Low-LET-Radiation ANP 
662-KeV gamma rays 100% Yes 
70-kVp X rays 100% Yes 
250-kVp X rays 100% No 
13.7 MeV neutrons 6% (from gamma rays) Yes 
5.9 MeV neutrons 6% (from gamma rays) No 
1.5-MeV neutrons 2% (from gamma rays) Yes 
0.44-MeV neutrons 1% (from gamma rays) Marginal 
0.22-MeV neutrons 1% (from gamma rays) No 
aThe recoil proton contribution to the dose was not assessed. 
8. Health Risks from High-Level Alpha Radiation Exposure  
Health risk from high-level exposure to alpha radiation from inhaled PuO2 aerosols has 
been extensively reported (Scott et al. 1990; Scott and Peterson 2003; Scott 2004b, 2005b,c). 
Here we summarize some of our more recent results (Scott 2007f) that relate to ingestion 
exposure to 210Po. 
The incident in London during November 2006 involving a lethal intake by Mr. Alexander 
Litvinenko of the highly-radioactive, alpha-particle-emitting isotope 210Po sparked renewed 
interest in the area of 210Po toxicity to humans. Because of the worldwide interest and wild, 
unfounded speculations in the news media, we quickly assembled information related to early 
studies of 210Po toxicity and used our hazard function (HF) acute-lethality-risk model (Scott 
2004b) to assess likely lethal intakes of 210Po for adults. Key findings were discussed in the 
indicated paper by Scott (2007f) and some were also incorporated into another paper by 
Harrison et al. (2007).  
The HF model (Scott et al. 1990; Scott and Peterson 2003; Scott 2004b, 2005b,c) was 
developed to address radiation exposure scenarios involving combined exposures to alpha, 
beta, and gamma radiations and can be used in circumstances where only one type of radiation 
is involved. Under a plausible set of assumptions (Scott 2007f) and using available 
megabecquerel (MBq) 210Po intake to gray dose conversion factors, acute lethality risk vs. dose 
curves were developed for circumstances of human exposure to 210Po by ingestion. Initial risk 
calculations were carried out for a reference adult male human (a hypothetical 70-kg person). 
Results were then modified for application to all ages (except the in utero child) via the use of a 
systemic (in blood) 210Po burden that is assumed to apply to all modes of lethal intake. Because 
of the unavailability of acute lethality data derived from humans ingesting high levels (based on 
radioactivity) of 210Po, the plausibility of risk calculations were evaluated based on data from 
studies of 210Po injections in animals. The animal data, although limited, were found to be 
consistent with the theoretical risk calculations.  
 32 
Key findings were as follows: 
• Ingestion (or inhalation) of a few tenths of a milligram of 210Po will likely be fatal to all 
exposed persons. 
• Lethal intakes are expected to involve fatal damage to the bone marrow, which is 
likely to be compounded by severe damage caused by higher doses to the kidneys 
and liver. 
• Lethal intakes are expected to cause severe damage to the kidney, spleen, stomach, 
small and large intestine, lymph nodes, skin, and testes (males) in addition to fatal 
damage to bone marrow. 
• The time distribution of deaths is expected to depend on the level of radioactivity 
ingested or inhaled, with deaths occurring within about 1 month after very high levels 
of radioactivity intake (e.g., systemic burdens > 1 MBq/kg-body-mass) and occurring 
over longer periods, possibly up to or exceeding 1 year for lower but lethal intakes 
(systemic burdens from 0.1 to 1.0 MBq/kg-body-mass). 
• Below a systemic burden estimate of 0.02 MBq/kg-body-mass, deaths from 
deterministic effects are not expected to occur but the risk of cancer and life 
shortening could be significant. 
• New, funded experimental and modeling/theoretical research is needed to improve on 
these estimates. 
We also compiled a Po-210 Information Sheet that is available through our project-
supported website: http://www.radiation-scott.org/Polonium%20Fact%20Sheet_SM_C.htm.  
9. Project Productivity 
This project has accomplished all of its goals. We have achieved an impressive number of 
scientific publications and presentations (Sections 11 and 12) that include two Nova Publisher 
book chapters. 
Annual project reports to DOE/BER were submitted in a timely manner for each the four 
years of this project. Our HRR model for radiation-induced cancer has attracted wide interest, 
as reflected by the numerous invitations for giving scientific presentations related to our 
research. This includes invited presentations at the National Institute of Allergy and Infectious 
Diseases, at Los Alamos National Laboratory, and at meetings sponsored by (1) the American 
Nuclear Society related to probabilistic risk analysis; (2) the DOE, related to their Low Dose 
Radiation Research Program; (3) the International Hormesis Society; (4) the Rio Grande 
Chapter of the Health Physics Society; and (4) Doctors for Disaster Preparedness. In addition, 
we assisted the U.K. Health Protection Agency in assessing toxicity to humans from ingested 
210Po that resulted in two publications that have attracted wide interest.  Key information on 
210Po toxicity was provided to ABC News personnel at their request. Key research findings have 
been published in peer-reviewed journals (see Section 11).  
10. Personnel Supported 
A number of talented persons have contributed to this project. They are listed below. 
Co-investigators at the SUBI: Dr. Z. B. Tokarskaya, Dr. G. V. Zhuntova, Dr. S. V. Osovets, 
Dr. Z. D. Belyaeva, Dr. V. Pesternikova (now retired), Dr. V. F. Khrokhryakov, and Dr. N. D. 
Okladnikova (now retired)  
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Co-investigators at Mayak PA: Dr. V. Syrchikov and Dr. E. K. Vasilenko 
Translators at SUBI: O. Danilova, A. Danilova, and O. Lifanova  
Graduate Student at LRRI: M. Haque 
Undergraduate Student and Administrative Assistant at LRRI: J. Di Palma 
11. Publications 
Publications fully or partially supported by this DOE/BER project are listed below (PR = 
peer-reviewed; NPR = not peer-reviewed): 
Belyaeva ZD, Osovets SV, Scott BR, Zhuntova GV, and Grigoryeva ES (2007, submitted). 
Respiratory system dysfunction among nuclear workers. Dose-Response. [PR] 
Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, Cedergreen N, Cherian 
MG, Chiueh CC, Clarkson TW et al. (2007). Biological stress response terminology: 
Integrating the concepts of adaptive response and preconditioning stress within a 
hormetic dose-response framework. Toxicol Appl Pharmacol 222:122-128. [PR] 
Day TK, Zeng G, Hooker AM, Bhat M, Scott BR, Turner DR, and Sykes PJ (2006). Extremely 
low priming doses of X radiation induced and adaptive response for chromosomal 
inversions in pKZ1 mouse prostate. Radiat Res 166:757-766. [PR] 
Day TK, Zheng G, Hooker AM, Bhat M, Scott BR, Turner DR, and Sykes PJ (2007). Adaptive 
response for chromosomal inversions in pKZ1 mouse prostate induced by low doses of X 
radiation delivered after a high dose. Radiat Res 167:682-692. [PR] 
Okladnikova ND, Osovets SV, and Kudryavtseva TI (2005a). Plutonium-239 and chromosomal 
aberrations in human peripheral blood lymphocytes. Radiobiology and Radioecology (in 
Russian) [PR]. 
Okladnikova ND, Scott BR, Tokarskaya ZB, Zhuntova GV, Khokryakov VF, Sirchikov VA, and 
Grigorieva ES (2005b). Level of stable and non-stable chromosome aberrations in 
incorporation of non-transportable 239Pu compounds. Medical Radiology and Radiation 
Safety 50(6):23-32 (in Russian).[PR] 
Okladnikova ND, Tokarskaya ZB, Scott BR, Zhuntova GV, Khokhryakov VF, Syrchikov VA, and 
Grigoryeva ES (2005c). Chromosomal aberrations in lymphocytes of peripheral blood 
among Mayak facility workers who inhaled insoluble forms of 239Pu. Radiat Prot Dosimetry 
113(1)3-13. [PR] 
Osovets SV (2005). Dose rate factor at assessment and modeling of deterministic effects at 
external exposure. Medical Radiology and Radiation Safety 50:12-17 (in Russian). [PR] 
Rithidech K and Scott BR (2007). Evidence for radiation hormesis in human lymphocytes. Dose-
Response (submitted). [PR] 
Sanders CL and Scott BR (2007, in press). Smoking and hormesis as confounding factors in 
radiation pulmonary carcinogenesis. Dose-Response. [PR] 
Scott BR (2004a). A biological-based model that links genomic instability, bystander effects, and 
adaptive response. Mutat Res 568:129-143. [PR] 
Scott BR (2004b). Health risks from high-level radiation exposures from radiological weapons. 
Radiat Prot Management 21(6):9-25. [NPR] 
Scott BR, Walker DM, and Walker VE (2004). Low-dose radiation and genotoxic chemicals 
protect against stochastic biological effects. Nonlinearity Biol Toxicol Med 2:185-211. [PR] 
 34 
Scott BR (2005a). Evaluating residual risks for lethality from deterministic effects after 
application of medical countermeasures against damage from inhaled radioactivity 
dispersal device released gamma-emitting radionuclides. Radiat Protec Management 
22(3):7-26. [NPR] 
Scott BR (2005b). Low-dose radiation risk extrapolation fallacy associated with the linear-no-
threshold model. BELLE Newsletter 13(2), Part 2:22-27, December 2005. [NPR] 
Scott BR (2005c). Stochastic thresholds: A novel explanation of nonlinear dose-response 
relationships. Dose-Response 3:547-567. [PR] 
Scott, BR and Guilmette RA (2005). Radiation Toxicology, Ionizing and Nonionizing. In 
Encyclopedia of Toxicology (P. Wexler, editor), Elsevier Limited, Oxford, Volume 3, 
pp. 601-614. [NPR] 
Scott BR (2006). Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 
98(8):561(Correspondence). [NPR] 
Scott BR (2007a). Health risk evaluations for ingestion exposure of humans to polonium-210. 
Dose-Response 5:94-122. [PR] 
Scott BR (2007b). Low-dose radiation-induced protective process and implications for risk 
assessment, cancer prevention, and cancer therapy. Dose-Response 5(2):131-149. [PR] 
Scott BR. (2007c). Natural background radiation-induced apoptosis and the maintenance of 
mammalian life on earth. In: Vinter CV (ed.), New Cell Apoptosis Research, Nova 
Sciences Publishers, Inc. Hauppage, NY, pp. 1-35. [NPR] 
Scott BR (2007, in press). It’s time for a new low-dose-radiation risk assessment paradigm — 
one that acknowledges hormesis. Dose-Response. [PR] 
Scott BR (2007, in press). Low-dose radiation risk extrapolation fallacy associated with the 
linear-no-threshold model. J Human Exper Toxicol. [NPR] 
Scott BR ( 2007). Radiation hormesis and the control of genomic instability. In: Gloscow EJ (ed), 
New Research on Genomic Instability. Nova Sciences Publishers, Inc. Hauppage, NY, pp. 
139-180. [NPR] 
Scott BR and Di Palma J (2006). Sparsely ionizing diagnostic and natural background radiations 
are likely preventing cancer and other genomic-instability-associated diseases. Dose-
Response 5:230-255. [PR] 
Scott BR, Haque M, and Di Palma J (2007, in press). Biological basis for radiation hormesis in 
mammalian cellular communities. International Journal of Low Radiation. [PR] 
Scott BR (2007, submitted). Low-dose-radiation stimulated natural chemical and biological 
protection against lung cancer. Dose-Response, submitted. [PR] 
Tokarskaya ZB, Zhuntova GV, Scott BR, Khokhryakov VF, Belyaeva ZD, Vasilenko EK, and 
Syrchikov VA (2006). Influence of radiation and non-radiation risk factors on the incidence 
of malignant liver tumors among Mayak PA workers. Health Phys 91(4):296-310. [PR] 
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12. Interactions 
12.1 Invited Presentations and Other Activities by B. R. Scott that Involved Interactions with 
Research Peers 
Invited speaker, Society of Toxicology Roundtable on low-dose extrapolation of cancer risks, 
2004. 
Invited presentation, “Low-dose radiation-induced protective process and implications for risk 
assessment, cancer prevention, and cancer therapy.” International Hormesis Conference, 
University of Massachusetts, Amherst, MA, June 8-10, 2004. 
Invited Plenary Session presentation, “Stochastic thresholds: A novel explanation for nonlinear 
dose response.” Plenary session presentation, International Hormesis Conference, 
University of Massachusetts, Amherst, MA, June 6-8, 2005. 
Invited session chair, session organizer, International Hormesis Conference, 2005, 2006, 2007. 
Invited LNT Plenary Session participant, “The LNT hypothesis may have outlived its usefulness 
for low-LET radiation.” American Nuclear Society Meeting Plenary Session on “Has the 
LNT outlived its usefulness?” San Francisco, CA September 13, 2005. 
Invited seminar, “The LNT hypothesis may have outlived its usefulness.” Los Alamos National 
Laboratory, November 10, 2005. 
Invited seminar, “The LNT hypothesis vs. radiation hormesis: Implications for managing 
radiological terrorisms events.” NIAID/NIH, Bethesda, MD, February 14, 2006. 
Invited plenary presentation, “The LNT hypothesis vs. radiation hormesis: Implications for 
managing radiological terrorisms events.” Rio Grande Chapter, Health Physics Society 
Meeting, Albuquerque, NM, June 2, 2006. 
Invited presentation, “Alternative radiation risk models that include a system of protective 
processes.” Workshop, Diagnostic Imaging Radiation-Associated Risk-Benefit: A 
Resource for Clinicians, Kansas City, MO, June 10, 2006. 
Invited Medical Session presentation, “Medical and therapeutic radiation hormesis: Preventing 
and curing cancer.” International Conference on Hormesis, June 6-8, 2006. 
Invited presentation, “Low-dose/dose-rate low-LET radiation protects us from cancer.” 
DOE/BER Low Dose Investigator’s Workshop, Washington, DC, July 31-August 2, 2006. 
Invited presentation, Radiation Carcinogenesis Workshop, NIH/NCI, Bethesda, MD, September 
10-12, 2006. 
Invited presentation, “Its time for a new low-dose radiation risk assessment paradigm—one that 
acknowledges hormesis.” The 6th International Conference on Hormesis: Implications for 
Toxicology, Medicine and Risk Assessment, University of Massachusetts, Amherst, MA, 
May 1-2, 2007.  
Invited Keynote Presentation, “Polonium-210: A highly toxic substance.” Rio Grande Chapter 
Health Physics Society Meeting, Hilton, Santa Fe, NM, May 4, 2007. 
Invited Presentation, “Low level radiation and health.” 25th Annual Meeting Doctors for Disaster 
Preparedness, "Category 5 Denial" vs. Confirming the Real Threats to America. Hilton 
Oakland Airport Hotel, Oakland, CA, August 3-5, 2007. 
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12.2 Other Project-Related Presentations Involving Interactions with Research Peers 
Belyaeva ZD, Zhuntova GV, Osovets SV, and Grigoryeva ES. "Influence or radiation and 
smoking on respiratory function among nuclear enterprise Mayak PA.” Fifth Russian 
Congress on Occupational and Health, Moscow, Russia, October 30 – November 2, 
2006 (in Russian). 
Di Palma J, “The implications of radiation hormesis: A student's understanding.” Poster 
presentation, University of New Mexico Undergraduate Research and Creativity 
Symposium, Albuquerque, New Mexico, November 21, 2005. 
Di Palma J and Scott BR, “Expected lives saved due to medical, therapeutic, environmental and 
other forms of radiation hormesis.” Poster presentation, 5th International Conference on 
Hormesis: Implications for Toxicology, Medicine and Risk Assessment, University of 
Massachusetts, Amherst, Massachusetts, June 6-8, 2006. 
Osovets SV, Belyaeva ZD, Scott BR, Tokarskaya ZB, Zhuntova GV, and Grigorieva ES. 
“Threshold model for estimation of external respiration indexes in combined chronic 
plutonium and smoking exposure on Mayak PA workers.“ Third International Symposium 
“Chronic radiation exposure: Biological and health effects”, Chelyabinsk, October 24-26, 
2005. 
Scott BR. “New data support revised low dose extrapolation models.” Presentation in 
Roundtable on “Low-Dose Extrapolation: Time for a Fresh Look at an Old Problem.” 43rd 
Annual Meeting & ToxexpoTM of the Society of Toxicology, Baltimore, MD, March 21-25, 
2004. Video of the roundtable available via http://www.radiation-scott.org. 
Scott BR. “Low dose radiation induced protective apoptosis-mediated process.” 51st Annual 
Meeting of the Radiation Research Society, St. Louis, Missouri, April 24-27, 2004. 
Scott BR. “A little dab of radiation could protect us from cancer.” Seminar presented at Lovelace 
Respiratory Research Institute, Albuquerque, New Mexico, June 21, 2004. 
Scott BR. “Stochastic thresholds cause nonlinear dose-response curves for mutations and 
neoplastic transformation.” DOE/BER Workshop on Biologically-Based Modeling of 
Human Health Effects of Low Dose Ionizing Radiation. Fred Hutchinson Cancer Research 
Center, Seattle, Washington, July 28-29, 2005.  
Scott BR. “Background radiation may be protecting us from cancer and other diseases.” 
Seminar presented at Lovelace Respiratory Research Institute, Albuquerque, New 
Mexico, August 8, 2005.  
Scott BR, Haque M, and Di Palma J, “Basic research results do not support the BEIR VII 
conclusion regarding the linear-no-threshold risk hypothesis.” Poster presentation at 9th 
International Conference on Environmental Mutagens and 36th Annual Meeting of the 
Environmental Mutagen Society, San Francisco, California, September 3-8, 2005.  
Scott BR, “Some new low-dose studies should relate to mechanistic basis for radiation 
hormesis.” Low Level Radiation Effects Summit, Carlsbad, New Mexico, Jan 15-18, 2006. 
Scott BR and Di Palma J, “Biological-based cancer hormetic relative risk model and implications 
for low dose radiation risk assessment, cancer prevention, and cancer therapy.” Poster 
presentation, Low Dose Investigator’s Workshop, Washington, D.C., July 31-August 2, 
2006. 
Tokarskaya ZB, Zhuntova GV, Scott BR, Belyaeva ZD, Khokhryakov VF, and Syrchikov VA. 
Factors of lung cancer risks in nuclear Mayak PA workers. 11th International Congress of 
the International Radiation Protection, Madrid, Spain, May 23-28, 2004. 
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Tokarskaya ZB. “Lung cancer in human and ionizing radiation (review of current literature).” 
Presentation given at the Southern Urals Biophysics Institute, June 13, 2006.  
Zhuntova GV, Tokarskaya ZB, Belyaeva ZD, and Sirchikov VA. "Role of radiation exposure in 
stomach cancer occurrence in Mayak PA personnel." Third International Symposium 
“Chronic radiation exposure: Biological and health effects”, Chelyabinsk, October 24-26, 
2005. 
Zhuntova GV, Tokarskaya ZB, Belyaeva ZD, Syrchikov VA, and Grigoryeva ES. "Influence of 
radiation and non-radiation factors on pancreatic cancer incidence among Mayak PA 
workers. Second European Congress on Radiation Protection, Paris, France, May 15-19, 
2006. 
Zhuntova GV, Tokarskaya ZB, Belyaeva ZD, Syrchikov VA, and Grigoryeva ES. "Radiation and 
non radiation risk factors effect on the large intestine cancer morbidity among Mayak 
nuclear workers." 28th International Congress on Occupational Health, Milan, Italy, June 
11-16, 2006. 
Zhuntova GV, Tokarskaya ZB, Belyaeva ZD, Grigoryeva ES, and Syrchikov VA. “Kidney cancer 
risk factors among Mayak PA workers”, Fourth International Scientific-and-Practical 
Conference, Medical and Ecological Effects of Ionizing Radiation, Tomsk, Russia, April 
11-13, 2007 (in Russian). 
Zhuntova GV, Tokarskaya ZB, Belyaeva ZD, Grigoryeva ES, and Syrchikov VA. "Multivariate 
analysis of radiation and non-radiation risk factors influence on kidney cancer incidence 
among Mayak PA workers. 13th International Congress of Radiation Research, San 
Francisco, CA, USA July 7-12, 2007. 
12.3 Project Related Website 
Our project-related website provides additional information related to radiation inducted 
stochastic and deterministic effects: http://www.radiation-scott.org . 
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13. Transitions 
Through our DOE/BER-supported research, we have assisted the scientific communities 
worldwide in becoming better aware of health risks associated with exposure of humans to Pu 
isotopes. In addition, we have informed the research community about the serious 
consequences of using the LNT cancer risk model for regulating radiation worker and the public 
exposures to ionizing radiation. The LNT risk model creates phantom excess risk at low doses 
for most exposure scenarios of interest that involve low-LET radiation or low- plus high-LET 
radiation. This is especially true for exposures involving residual radioactivity after remediation 
of radionuclide-contaminated DOE sites. 
Through our many publications, seminars, and presentations at scientific meetings we 
have alerted the scientific community to the enormous potential for using low-LET-radiation ANP 
for both preventing future cancers in high risk groups of individuals and for the possibility of 
combining low-dose-radiation ANP with other agents (e.g., biological [gene therapy] and/or 
chemical [e.g., resveratrol]) that sensitize cancer cells to undergo apoptosis in order to cure 
existing cancer with a low-dose paradigm (e.g., multiple low, harmless doses of diagnostic X-
rays plus resveratrol). Low-dose radiation therapy would eliminate the type of patient suffering 
that is associated with the current high-dose radiation and chemotherapies which destroys large 
amounts of normal tissue. Multiple, essentially harmless doses (milligray quantities) of X-rays 
spread over an extended period, for example, could be used in treating lung and other cancers. 
Our risk modeling of deterministic radiation effects proved to be very beneficial to the world 
community after the death of the Mr. Alexander Litvinenko last November in London, due 210Po 
exposure. We began quickly researching this largely forgotten alpha-emitting radioisotope. We 
also collaborated with other radiation research experts including scientist at the Health 
Protection Agency (HPA) in London responsible for managing the incident. The research led to 
a publication on 210Po toxicity (Scott 2007f) as well as another joint publication with John 
Harrison (first author) of the HPA entitled "Polonium-210 as a Poison" that was published in the 
March 2007 issue of the Journal of Radiological Protection. A feature article about our timely 
210Po research entitled "One of the Most Dangerous Radioisotopes Known to Man: Polonium-
210" was published by our Institute in its Spring 2007 issue of the Gift of Breath newsletter that 
was circulated in the United States. We also assisted ABC News personnel in understating the 
toxicity of 210Po to humans at their request. 
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16. Future Work 
Although there is need for future work related to toxicity to humans from low- and high- 
level exposures to radionuclides and external radiation (e.g., gamma rays, neutrons, protons), 
there is currently no DOE research program that is funding such research. New research that 
focuses on cancer prevention and cancer cures using low-dose-radiation ANP would also be 
quite beneficial to mankind. Modeling/theoretical and experimental research related to 
evaluating residual risk of acute lethality after application of medical countermeasures following 
a dirty bomb incident involving the intake of large quantities of radionuclides would also be quite 
beneficial. While our research group is quite capable of conducting such research, currently 
there are no DOE research programs that support such research. Epidemiological studies 
specifically designed to reveal low-dose-radiation ANP would also be quite beneficial in light of 
the misleading information published in the BEIR VII Report regarding cancer risks from low 
dose radiation. A combined case-control and cohort design would be expected to be optimal, 
allowing for controlling for confounders and addressing the systematic error introduced by 
including low-dose persons (possibly with ANP) in the control (unirradiated) group. Our research 
team is also quite capable of conducting such studies and would be happy to participate in such 
research should funding opportunities become available in the near future. 
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Abstract 
This appendix summarizes previous work carried out related to theoretical modeling of 
plutonium-dioxide (PuO2) aerosols deposition in the human respiratory tract and experimental 
results related to respiratory filter efficiencies for preventing inhalation intake of the high-density 
material (surrogates for PuO2). Results that follow were reported in a previous Department of 
Energy project final report with the same title as the current renewal project. The results are 
being reported here because of their relevance to the current project. 
1. Theoretical Approach to Estimating Plutonium Dioxide Intake via Inhalation 
Here, we summarize our theoretical approach to calculating radioactivity intake 
distributions for populations of individuals with varying breathing characteristics. The approach 
helps to explain the large variability in radioactivity intake by inhalation observed in association 
with the Los Alamos, New Mexico, incident on March 16, 2000 (Table 1), where a glovebox 
leaked high-specific-activity, alpha-emitting (HAS-αE) plutonium dioxide-238 (238PuO2) to room 
air, which was inhaled by at least some of the eight workers in the room. Scientists at our 
Institute participated in characterizing the source term for the Los Alamos incident. 
Table 1.  Nasal-swipe measurement for 238Pu for eight Los Alamos workers involved in the 
March 16, 2000, glovebox incident at the Pu Processing and Handling Facility (TA-55) 
(DOE, 2000). 
Affected Employeea Nasal Swipe Results (dpm)b (left nostril/right nostril) 
ET 99,271/68,536 
RCT-1 5,807/1,161 
RCT-2 1,048/193 
CPT-1 2,502/NDAc 
CT-2 159/NDAc 
CPT-3 NDA/NDAc 
CPT-2 NDA/NDAc 
CT-1 NDA/NDAc 
aET = Electrical Mechanical Technician (one person); RCT = Radiological Control 
Technician (two persons); CPT = Chemical Process Technician (three persons);  
CT = Chemical Technician (two persons). bdpm = disintegrations per minute; cNDA = no 
detected amount. 
1.1 Single-Particle-Associated Radioactivity Intake Distributions 
We indicate the single-particle-associated radioactivity intake distribution as f1(A|pop, 
aero), where A is the radioactivity intake associated with the single particle deposited in the 
respiratory tract (e.g., specific region) via inhalation; the abbreviation pop (for populations) 
accounts for all the key population characteristics (distributions); and the abbreviation aero (for 
aerodynamic) accounts for the aerodynamic characteristic of the aerosol considered. The 
vertical bar “|” is used to indicate that the amount of radioactivity, A, deposited in the respiratory 
tract as a result of a single-particle deposition event depends on the population characteristics 
(pop) in addition to the aerodynamic characteristic (aero) of the aerosol. For a heterogeneous 
population, pop accounts for all relevant distributions (e.g., distribution in breathing frequencies, 
in tidal volumes, in fraction of air entering via the nose, etc.). For reference individuals (e.g., a 
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70-kg reference adult male), pop would then relate to fixed values for these variables assigned 
to the reference individual. Our early publications were based on reference individuals (Scott et 
al. 1997; Scott and Fencl 1999). This work relates to populations (i.e., a large group) of 
individuals (e.g., adult male workers involved in light, work-related exercise).  
For a reference individual, the distribution f1(A|pop, aero) depends on the region of the 
respiratory tract, the individual’s age, the physical activity level, and the particle size distribution 
Φ(d), where d is the aerodynamic diameter. For a heterogeneous population (e.g., adult male 
workers) with different breathing characteristics, the calculated distribution f1(A|pop, aero) 
depends on the distributions assigned to key respiratory variables and parameters. Our 
calculations (explained in detail in Aden and Scott 2003) are based on distributions published by 
Bolch and colleagues (2001) that relate to their stochastic version of the International 
Commission on Radiation Protection (ICRP) 66 respiratory tract dosimetry model (ICRP 1994).  
The product f1(A|pop, aero)dA gives the fraction of single-particle associated radioactivity 
intakes (via single particles) with radioactivity in the very small interval (A, A+dA). The 
distribution f1(A|pop, aero) does not depend on particle presentation (defined below), Ω, but 
accounts for particle inhalability, PI(d), and particle deposition probability, PDep(d) (Scott et al., 
1997; Scott and Fencl, 1999). In addition, both PI(d) and PDep(d) depend on particle density, 
size, and shape. 
The presentation, Ω, is the mean number of particles presented to a human receptor for 
inhalation over the period of interest (Scott et al., 1997). For the stochastic intake (StI) 
paradigm, the number of particles presented can be presumed to come from a Poisson 
distribution (Scott et al. 1997; Scott and Fencl, 1999). We have used the notation P(n|Ω) to 
indicate the Poisson probability that exactly the number, n, of airborne particles of interest are 
presented to an individual for inhalation during the period of interest. P(n|Ω) is useful for 
conducting evaluations over many inhalations (breaths) and is related to the particle availability, 
PA(d), which is associated with a single breath (Scott et al., 1997). 
The PA(d) represents the 
probability that a particle of 
interest will be contained in a 
tidal volume of air just before 
inhaling (Scott et al., 1997). 
Calculated availability of 
monodisperse, low-specific-
activity, alpha-emitting (LSA-αE) 
and HSA-αE PuO2 aerosols is 
presented in Figure 1 as a 
function of particle equivalent-
volume diameter, dev, when the 
air radioactivity concentration is 1 
DAC (derived air concentration) 
(Scott et al., 1997). Calculations 
were based on a 1.3-L tidal 
volume, a particle density of 10 
g/cm3 (Kotrappa et al., 1972; 
Raabe, 1994), and ICRP 
Publication 30 DACs (ICRP, 
1979). 
Figure 1. Availability of airborne, monodisperse, PuO2 particles 
evaluated at the derived air concentration (Scott et al., 1997). 
 A-4 
The dev, is the diameter of a sphere with the same density and mass as the particle of 
interest. Use of equivalent-volume diameter facilitates evaluating particle radioactivity for 
irregularly shaped particles. We calculate equivalent-volume diameter using mathematical 
equations presented in ICRP Publication 66 (1994). 
For the StI paradigm, where at most relatively small numbers of airborne particles are 
inhaled, the particle presentation Ω and associated Poisson probability, P(n|Ω), are important in 
characterizing the variability of the unconditional intake of radioactivity (Scott and Fencl, 1999).  
1.2 Convolution Method for Multiple Particle Intakes 
The radioactivity intake distribution for inhaling two particles of interest, sampled by 
inhalation from an airborne particle-size distribution, Φ(d), is given by f2(A|pop, aero) where 
 ∫ −= A dxxAfxfAf
0
.)aero pop,|()aero pop,|()aero pop,|( 112  (1) 
The integral and those that follow can be evaluated numerically as described elsewhere 
(Aden and Scott 2003). The radioactivity intake distribution for inhaling three particles of 
interest, sampled from a given Φ(d), is given by f3(A), where 
 ∫ −= A dxxAfxfAf
0
.)aero pop,|()aero pop,|()aero pop,|( 213  (2) 
Similarly, for n + 1 particles the radioactivity intake distribution is given by 
 .)aero pop,|()aero pop,|()aero pop,|(
0
1 1∫ −=+
A
n dxxAfxfAf n  (3) 
We were not able to develop an analytical solution for f1(A|pop, aero). However, an 
empirical distribution was developed based on particle-size-dependent deposition efficiencies 
(adjusted for inhalability) associated with our stochastic version (Crystal Ball based 
[Decisioneering, 1996]) of the ICRP 66 respiratory tract deposition model. The convolutions for 
multiple-particle intake were carried out via the standard Monte Carlo method using our Crystal 
Ball program developed by Jay Aden and Pamela Longmire (both were graduate students when 
they were at our Institute). The use of Crystal Ball software facilitates the later addition of risk 
distribution calculations. As opposed to a programming language such as Fortran Visual Basic 
or C++, Crystal Ball provides a much more user-friendly and efficient way for obtaining summary 
statistics and graphics for the distributions generated, and facilitates outputting distribution data 
generated for use in other analyses. It also allows the parameter values and distributions to be 
easily adjusted for other genders and age groups. The Crystal Ball software runs inside of 
Excel, which allows use of Excel macros. The output of the Monte Carlo evaluations is an 
empirical radioactivity intake distribution that varies because of sampling, via inhalation, from a 
distribution Φ(d) and because of sampling over-distributions of respiratory parameters and 
variables representative of the population of interest. 
Particle radioactivity was calculated via a macro that accounted for particle shape, mass, 
etc., and converted aerodynamic diameter d to the equivalent-volume diameter dev.  
Inhaling relatively small amounts of PuO2 via resuspended PuO2-contaminated soil could 
cause lung, liver, and bone cancers in the general population (e.g., citizens who live near Rocky 
Flats). Inhaling large amounts of PuO2 in the nuclear workplace could lead to radiation 
deterministic effects such as radiation pneumosclerosis (Okladnikova, 1994b). Radiation 
pneumosclerosis is a disease observed among Mayak Production Association (PA) workers that 
inhaled large amounts of 239Pu, possibly milligram quantities (Scott and Peterson, 2003). Thus, 
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for years, environmental and workplace exposure to Pu and associated health risks have been 
topics of interest to many scientists and clinicians (Altman et al., 1992; DOE/EPA/CDPHE, 
1996; Gilbert et al., 2000; Hoover and Newton, 1993; Kreisheimer et al., 2000; Koshurnikova 
et al., 2000; Jones and Zhang, 1994; NCRP, 1996, 1999; Newton et al., 1986, 1987; 
Okladnikova and Burak, 1993; Okladnikova et al., 1992a, b, 1993, 1994a, b; RSALOP 1999a-d; 
Scott, 1995; Scott et al., 1990, 1993; Tokarskaya and Basogolov, 1995; Tokarskaya and 
Khokhryakov, 1975; Tokarskaya et al., 1995, 2002; US DOE, 1996)  
We carried out basic and applied research related to developing improved radiation 
dosimetry and risk estimates to facilitate environmental management of Pu-contaminated sites. 
Our early research focused largely on the StI paradigm, where some of the at-risk population 
may inhale relatively large amounts of radioactive particles while other may inhale none. Similar 
consideration would apply to polonium-210 aerosols. Some consideration has also been given 
to the deterministic intake (DI) paradigm, where every member of the at-risk population would 
be expected to inhale large numbers of radioactive particles. As may be expected, the StI 
paradigm relates to relatively small numbers of LSA-αE or HSA-αE PuO2 particles being 
presented for inhalation (e.g., particles that penetrate respirator filters when carrying out 
deactivation and decommissioning [D&D] operations in PuO2 environments). Examples of HSA-
αE particles are 236PuO2, 238PuO2, 240PuO2, 241AmO2 (americium-241 dioxide) and 242CmO2 
(curium-242 dioxide). Examples of LSA-αE particles are 239PuO2, 242PuO2, and 244PuO2 (Scott 
et al., 1997). 
For the DI paradigm, every person who inhales the radionuclide-contaminated air takes in 
radioactivity with essentially a probability equal to 1. There is no issue of whether a person has 
intake. In contrast, with the StI paradigm, some individuals may have intakes but others may not 
for the same incident, same duration of exposure, and same location (e.g., same room). Our 
research has demonstrated that for the StI paradigm, point estimates of radioactivity intake and 
associated dose are highly unreliable, and instead should be replaced by distributions for 
possible intakes and doses (Scott et al., 1997; Scott and Fencl, 1999; Aden and Scott, 2003). 
With the distribution framework, each possible intake of radioactivity as well as each absorbed 
radiation dose will have an associated probability.  
We previously constructed theoretical, conditional PuO2 intake (via inhalation) 
distributions for adult males engaged in light work-related exercise, using the convolution 
method briefly summarized below. The conditioning relates to the number of particles inhaled. 
For example, the conditioning could be that exactly 10 PuO2 particles are inhaled and deposited 
in the respiratory tract (or specific region or subregion) from airborne PuO2 (with a specified 
particle size distribution and physical characteristics). Table 2 gives summary statistics for 
calculated radioactivity intake for exactly 1, 10, or 100 PuO2 particles depositing throughout the 
respiratory tract of adult male workers engaged in light work-related exercise and not wearing 
respirators (Aden and Scott, 2003). For these evaluations, variability between different 
individuals in physiological and anatomical characteristics was accounted for using a stochastic 
version of the ICRP 66 respiratory tract deposition model implemented with Crystal Ball 
software. Our stochastic version of the ICRP 66 particle deposition model is based on 
parameter and input variable distributions established by Bolch et al. (2001) in developing their 
FORTRAN-based, stochastic model known as LUDUC (LUng Dose Uncertainty Code). Our 
Crystal Ball software allows for particle polydispersity, which Bolch et al. (2001) did not address.  
Results presented in Tables 2 and 3 apply to a population (large group) of adult male 
worker engaged in light, work-related exercise. Variability indicated relates to sampling from a 
polydisperse particle size distribution and over a population with differing breathing 
characteristics. Evaluations were carried out for a log-normal distribution of PuO2 particle size 
distributions with an activity median aerodynamic diameter of 5 μm and geometric standard 
deviation of 2.5.  
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Table 2. Statistics for radioactivity from the deposition of 1, 10, and 100 particles 
(par) of weapons grade Pu in the respiratory tract of adult males engaged in light 
work-related exercise. Statistics are based on data measured in becquerels. 
Statistics 1 par 10 par 100 par 
Mean/n* 1.67 1.73 1.68 
Median/n* 0.1 0.631 1.39 
Mode/n* 0.03 0.172 0.964 
Std. Dev 9.75 34.4 104 
Variance/n* 95 119 108 
Skewness 11.80 5.17 1.61 
Kurtosis 168.37 38.5 6.61 
CVa 5.83 1.99 0.62 
Minimum <0.01 0.10 19.1 
Maximum 172 446 1060 
Std. Error 0.10 0.34 1.04 
*Indicated statistic has been divided by the number, n of particles deposited. 
aCoefficient of Variability 
 
Table 3. Statistics associated with calculated respiratory tract regional radioactivity intake  
for exactly 1, 10, or 100 particles of PuO2 depositing in the respiratory tract of adult males 
engaged in light work-related exercise. 
 
Particles 
(n) Mean/n Median/n Var*/n 
Skew-
ness 
Kur- 
tosis 
Coeff. 
variation Min Max 
 1 2.6 0.14 187 12.63 206.5 0.19 0 325 
ET1a 10 2.64 0.10 246 4.81 33.53 1.88 0.22 632 
  100 2.71 0.22 288 1.63 6.39 0.63 36.95 1,375
 1 2.56 0.09 331 16.94 350 0.14 0 470 
ET2 10 2.26 0.85 228 5.9 50.2 2.11 0.13 855 
  100 2.42 0.19 278 1.76 6.72 0.69 20.82 1,407
 1 0.28 0.041 1.44 21.43 758 0.23 0 52.19
BB 10 0.275 0.17 1.44 6.75 79 1.38 0.09 63.6 
  100 0.283 0.25 1.86 2.51 11.95 0.48 7.18 143 
 1 0.06 0.014 0.017 6.37 64.4 0.43 0 2.4 
bb 10 0.059 0.048 0.018 2.03 9.77 0.73 0.03 4.82 
  100 0.059 0.057 0.018 0.59 3.64 0.23 2.22 14.1 
 1 0.02 0.005 0.0016 5.58 47.7 0.45 0 0.78 
AI 10 0.02 0.017 0.002 1.75 8.01 0.7 0.01 1.6 
  100 0.02 0.02 0.002 0.57 3.52 0.22 0.88 4.18 
aRegions: ET (1 & 2), extrathoracic; BB, bronchial; bb, bronchiolar; Al, alveolar.  
bVar = variance. 
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The results in Table 2 and 3 apply to persons not wearing respirators. In Table 3 we 
divided the following statistics by the number of particles depositing in the indicated region of 
the respiratory tract: mean, median (Med), and variance (Var). We call the respective results: 
normalized mean, normalized median, and normalized variance. It can be seen that the 
normalized mean is quite stable for a given region (i.e., it is not influenced very much by the 
number of particles depositing in a given region). This is also true of the normalized variance. It 
can also be seen that with penetration into the respiratory tract, the mean radioactivity per 
particle (normalized mean) depositing greatly decreases between the extra thoracic region (ET) 
and the bronchial region (BB). Similar decreases are indicated for going from the BB to the 
bronchiolar (bb) region and from the bb region to the alveolar (Al) region. The reductions are not 
due to a reduced number of particles (since this number was fixed in our calculations) but to a 
shift in the particle size distribution toward smaller particles with penetration into the respiratory 
tract.  
In our previous publication (Aden and Scott 2003), we have compared our generated 
distributions for regional deposition efficiencies to deterministic results (point estimates) 
generated with the LUDEP computer program used by many to implement the ICRP 66 
deposition calculations. We found that LUDEP appears to involve a systematic error for the 
efficiency at which large particles deposit in the deep regions of the respiratory tract (greatly 
overestimating deposition). This systematic error would contribute to overestimating the risk for 
cancer induction when evaluated with a model that depends on absorbed dose to the pulmonary 
region. Further, it appears that LUDEP evaluates radioactivity deposition in the deep lung based 
on scaling the radioactivity presented for inhalation by the averaged particle deposition 
efficiency for the region. This appears to introduce systematic error in that the radioactivity 
distribution changes with penetration into the respiratory tract (See Aden and Scott 2003), 
whereas the method apparently used in LUDEP to calculate radioactivity deposition seems to 
assume that the radioactivity distribution (when normalized) is independent of the respiratory 
tract region. 
1.3 Using Conditional Intake Distributions 
The conditional distributions can be used to evaluate probabilities for exceeding, via 
inhalation, the intake of a specified amount of radioactivity (e.g., Annual Limit on Intake [ALI]). 
One of our earlier publications (Scott and Fencl, 1999) shows how to carry out the necessary 
calculations as well as how to address mixtures of different alpha-emitting isotopes. 
2. Respiratory Filter Penetration Concerns 
Earlier, it was recognized through routine monitoring of workers at Rocky Flats that 
employees who carried out D&D work occasionally showed Pu in their urine even though they 
were well protected (via special protective garments and devices [e.g., respirators]) in 
conducting their job duties. We have previously hypothesized that small high-density PuO2 
particles might with low frequency penetrate respirator filters, and over time the intake of PuO2 
could increase to detectable levels in urine.  
To test the indicated hypothesis, Yue Zhou and Yung-Sung Cheng previously conducted 
experimental, respirator filter penetration studies using high-density metal dioxide particles 
(CeO2, density = 7.65 g/cm3; HfO2, density = 9.68 g/cm3; and PbO2, density = 9.64 g/cm3). Test 
aerosols were generated by a small-scale powder disperser (SSPD, Model 3433, TSI Inc., St. 
Paul, MN). The SSPD consisted of a rotational disk coated with powder and a suction tube to 
take up the powders from the disk and disperse them as an aerosol. The aerosol was delivered 
at a flow rate of 22.5 L/min and passed into an 85Kr discharger tube to neutralize the particles, 
through a dilutor to maintain proper concentration, and into the test chamber where a flow 
laminator distributed the flow evenly. The test chamber was a cylinder (12 in. I.D. x 17 in. long), 
and the aerosol consternations were uniform. Pre-filter and post-filter probes were located in the 
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test chamber to sample the aerosol. An aerodynamic particle sizer (APS, TSI Inc.) was 
connected to the sample probes and measured the particle concentrations before and after the 
filter, from which the filter penetration frequency could be calculated. 
Three types of respirator filters were used in this study, according to the recommendations 
of the Department of Energy (DOE) laboratories contacted: 1) MSA P100 Multigas (Model 
00817887, MSA, Pittsburgh, PA), 2) Survivair 7000 Series MC-Multi-Contaminant/P100 
(Survivair, Santa Ana, CA), and 3) 3M 6000 Series Particulate P100 (Model 2091, 3M, St. Paul, 
MN). Hundreds of thousands of inlet particles were used. 
Mean penetration frequencies are presented in Table 4. The best performing filter was the 
3M. The worst performing filter was the Survivair. Thus, our results suggest that the Pu 
appearing in urine of workers at Rocky Flats may have arisen via respirator filter penetration 
events for small PuO2 particles (density approximately 10 g/cm3). As the number of work days 
(with protective garments and devices) in PuO2 environments increases, the intake of PuO2 
would be expected to increase to a level possibly detectable in urine. Thus, routine monitoring 
of workers’ urine (as appears is already being done at DOE facilities such as Rocky Flats) 
appears to be a good defendable practice. 
Table 4. Measured respirator filter penetration frequencies for high-density metal 
surrogates for PuO2a 
Average particles penetrating filter per million inlet particles 
High-density Metal 3M MSN Survivair 
CeO2 6.3 43.4 616 
HfO2 6.6 34.6 1178 
PbO2 (study #1) 6.9 6.4 53.8 
PbO2 (study #2) 15.3 10.3 35.4 
aMost airborne particles had aerodynamic diameters less than 12 μm. 
2.1 DI Paradigm: Inhaling PuO2 in Resuspended Dust 
We have conducted similar evaluations for inhalation exposure of members of the public 
to PuO2-contaminated soil. We have only carried out a calculation for reference male adults. 
However, the results can also be applied to reference female adults for a first approximation. 
Thus, the variability addressed here relates only to sampling from a polydisperse particle size 
distribution. Because the radioactivity is diluted by mixing with soil, the specific activity of the 
contaminated soil can be much lower than for pure PuO2. Thus, to inhale the same amount of 
radioactivity as that of pure metal PuO2, large numbers of contaminated dust particles may need 
to be inhaled (possibly over many years). We were interested in starting from the StI paradigm 
and systematically increasing the number of particles inhaled until we crossed the boundary 
between the StI and DI paradigms. 
Thus, for PuO2-contaminated soil we have evaluated conditional radioactivity intake 
distributions. We started from a single dust particle and by convolution generated conditional 
intake distributions for up to 5 million dust particles. Again, the numerical convolution approach 
was used. For Pu-contaminated soil, we used a density of 2 g/cm3 and a reference specific 
activity of 1 Bq/g (27 pCi/g) for PuO2-contaminated dust particles. With this approach, results 
can be scaled to any specific activity of interest for the soil/PuO2 combination. Evaluations were 
carried out for reference adult males engaged in light exercise based on respiratory tract 
parameters for males but are assumed to apply to both sexes. 
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Results for 100, 10,000, and or 1,000,000 dust particles are presented in Figures 2–4.  
 
Figure 2. Conditional radioactivity-intake distribution, f100(A|pop, aero), for a 100 PuO2-contaminated 
dust-particle intake by reference adults (Scott et al., 1999) when the contaminated dust has a 
specific activity of 1 Bq/g. The distribution was evaluated numerically based on 10,000 Monte Carlo 
trials, a polydisperse size distribution with an activity median aerodynamic diameter of 1 μm, and a 
geometric standard deviation of 2.5. 
 
 
 
Figure 3. Conditional radioactivity-intake distribution, f10,000(|pop, aero A), for a 10,000 PuO2-
contaminated, dust-particle intake by reference adults (Scott et al., 1999) when the contaminated 
dust has a specific activity of 1 Bq/g. The distribution was evaluated numerically based on 10,000 
Monte Carlo trials, a polydisperse size distribution with an activity median aerodynamic diameter of 1 
μm, and a geometric standard deviation of 2.5 
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Figure 4. Conditional, radioactivity-intake distribution, f1,000,000(A|pop, aero), for a 1,000,000 PuO2-
contaminated, dust-particle intake by reference adults (Scott et al., 1999) when the contaminated 
dust has a specific activity of 1 Bq/g. The distribution was evaluated numerically based on 10,000 
Monte Carlo trials, a polydisperse size distribution with an activity median aerodynamic diameter of 1 
μm, and a geometric standard deviation of 2.5. 
Note that as the number of particles deposited in the respiratory tract increases, the shape 
of the radioactivity intake distribution shifts from having a long tail to the right toward roughly a 
normal distribution with little variability. The 1,000,000-particle intake distribution is clearly in the 
deterministic paradigm as the variability in intake related to particle polydispersity (varying sizes) 
has almost vanished (compare max and min radioactivity values for the distribution). A more 
variable distribution is expected to emerge when we add variability in breathing characteristics 
as was done earlier for pure metal PuO2. Our earlier work suggests that when millions of dust 
particles are inhaled over years (as may occur for a family living at a remediated DOE site), 
variability in lifestyle may be a much more important influence on radioactivity intake than is 
variability in dust particle size distribution. Based on this research, specific recommendations 
were made related to developing final radionuclide soil action levels (RSALs) for the Rocky Flats 
site. These recommendations were placed on our Pu web site (www.radiation-scott.org) and 
presented at the American Chemical Society National Meeting & Exposition, New Orleans, LA, 
August 22-26, 1999 (Scott et al., 1999).  
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Abstract 
The current system of radiation protection for humans is based on the linear-no-threshold 
(LNT) risk-assessment paradigm.  Perceived harm to irradiated nuclear workers and the public 
is mainly reflected through calculated hypothetical increased cancers.  The LNT-based system 
of protection employs easy-to-implement measures of radiation exposure.  Such measures 
include the equivalent dose (a biological-damage-potential-weighted measure) and the effective 
dose (equivalent dose multiplied by a tissue-specific relative sensitivity factor for stochastic 
effects).  These weighted doses have special units such as the sievert (Sv) and millisievert 
(mSv, one thousandth of a sievert).  Radiation-induced harm is controlled via enforcing 
exposure limits expressed as effective dose. Expected cancer cases can be easily computed 
based on the summed effective dose (person-sievert) for an irradiated group or population.  Yet 
the current system of radiation protection needs revision because radiation-induced natural 
protection (hormesis) has been neglected.  A novel, nonlinear, hormetic relative risk model for 
radiation-induced cancers is discussed in the context of establishing new radiation exposure 
limits for nuclear workers and the public. 
Indexing Terms: hormesis, radiation, adaptive response, risk assessment 
1. Introduction 
The current system of limiting human exposure to ionizing radiation is based on the 
premise that the risk of deleterious stochastic effects such as cancer increases as a linear-no-
threshold (LNT) function of the absorbed radiation dose (i.e., radiation energy deposited in 
tissue divided by the tissue mass). This is known as the LNT hypothesis and has no scientific 
basis. The linearly increasing risk function is also often called the LNT model.  Such a linear 
relationship, if correct, means that doubling the radiation dose doubles the risk of harm.  
Conversely, reducing the dose one million-fold is supposed to reduce the risk by the same 
factor. 
Some basic terminology is explained below to facilitate following the later sections of this 
paper.  
1.1 High- and Low-LET Radiations 
Two types of radiation (high and low linear energy transfer [LET]) are usually 
distinguished in characterizing radiation risks to humans. High-LET forms include alpha 
particles, neutrons, and heavy ions that produce intense ionization patterns when interacting 
with biological tissue.  Considerable energy is deposited when traversing a narrow thickness of 
tissue. Low-LET forms include x and gamma rays and beta particles that deposit far less energy 
when traversing a narrow thickness of tissue. 
1.2 Units for Expressing Radiation Doses 
Radiation dose is expressed in different ways depending on the intended usage. A 
fundamental unit is the absorbed radiation dose, which is a measure of energy deposited in 
tissue (or other material) divided by the mass irradiated.  Typical units of absorbed dose are the 
gray (Gy) which is equal to 1 joule/kg, and the milligray (mGy), which is one thousandth of a 
gray. These units can be applied when characterizing any type of radiobiological damage. 
For regulating radiation exposure of humans (e.g., setting radiation exposure limits) and 
for low-dose risk assessment, special radiation dose units have been established that are based 
on the linear-no-threshold [LNT] hypothesis.  These units are the result of applying statistical 
weights called radiation weighting factors (WR) to radiation-specific doses and are expressed in 
units such as the sieverts (Sv) and millisieverts (mSv). These weighted doses are called 
equivalent doses and can be added for a given tissue. To account for differing sensitivities of 
different tissue, a second set of weights called tissue weighting factors (WT) are employed to the 
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equivalent doses. The resulting weighted doses can also be added and the resultant dose is 
called effective dose and expressed in sieverts or millisieverts.  Under presumed LNT dose-
response functions for all cancer types, the effective dose represents the uniform gamma-ray 
dose to the total body that would incur the same overall cancer risk as is associated with the 
person’s actual exposure, irrespective of its nonuniformity and irrespective of the type and 
energies of the radiations that are involved.  
1.3 Radiation Dose Limits 
Human radiation exposures are limited for nuclear workers, the public, and other groups 
based on limiting the effective dose.  For example, the effective dose limit for nuclear workers is 
50 mSv/y and for the public is 1 mSv/y based on U.S. Department of Energy and Nuclear 
Regulatory Commission regulatory policies (Metting 2005).  The U.S. Environmental Protection 
Agency’s regulatory policy limits on release of radioactivity to air is based on limiting the 
effective dose to humans to 0.1 mSv/y, and for public drinking water the corresponding limit is 
0.04 mSv/y. For a point of reference, natural background radiation doses in the United States 
are associated with an effective dose of about 3 mSv/y (radon exposure included) (Metting 
2005). For Ramsar, Iran, the corresponding dose associated with natural background radiation 
is about 200 mSv/y.  Interestingly, such high background radiation doses appear to be 
associated with radiation hormesis-related protection against cancer (Frigèrio and Stowe 1976; 
Nambi and Soman 1987), i.e., a reduction in cancers. 
1.4 Low Dose/Dose Rate Cancer Risk Assessment within the LNT Framework 
Under the LNT risk assessment framework, effective doses for individuals can be added 
to obtained person-sievert (a collective dose) for population exposure, and the collective dose 
can be used to calculate the expected number of cancers among an irradiated population. 
Similarly, effective dose can be used to assign an individual specific cancer risk.  However, low 
doses are often delivered at low rates and a correction is made for a reduction in harm after low-
rate exposure as compared to high-rate exposure.  For low doses and dose rates, a low-dose 
and dose-rate effectiveness factor (DDREF) is used to reduce the slope of the cancer risk curve 
by a fixed amount, usually a factor of 2 (Mitchel 2006).  However with the LNT framework, 
reducing the effective dose by a factor of 2 has the same effect.  By using the LNT-based 
DDREF approach for low-dose, low-dose-rate risk assessment, one essentially dismisses the 
possibility of radiation-induced protective effects (hormesis), as the dose-response curve slope 
is constrained to be positive.  
1.5 Hormetic Dose-Response Curves 
With hormesis, low doses of radiation protect against cancer, leading to a negative slope 
in the low-dose region for the dose-response curve.  High doses, however, inhibit protection 
causing risk to then increase as dose increases.  This yields what has often been called a U- or 
J-shaped dose-response curve (Calabrese and Baldwin 2001 a,b; Calabrese 2004, 2005; 
Calabrese et al. 2006).   
2. Different Classes of Radiation-Associated Hormesis 
This paper distinguishes three classes of radiation hormesis based on the recent 
recommendations of Calabrese et al. (2007): 
5. Radiation conditioning hormesis: This form of hormesis relates to circumstances where a 
small radiation dose (mild stress) or moderate dose administered as a low rate (prolonged 
mild stress) activates protective processes that in turn suppress harm from a subsequent 
damaging large radiation dose.  
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6. Radiation hormesis: A small radiation dose (mild stress) or a moderate dose given at a 
low rate (recurring mild stresses) activates protective processes and reduces the level of 
biological harm to below the spontaneous level. 
7. Radiation post-exposure conditioning hormesis: Damage normally caused by a large 
radiation dose or large dose of some other agent is reduced as a result of a subsequent 
exposure to a small radiation dose (mild stress) or a moderate dose delivered at a low 
rate (repeated mild stresses). 
Sheldon Wolff’s group (Olivieri et al. 1984; Wolff 1989, 1996) were the first to demonstrate 
and publish radiation conditioning hormesis data. When human lymphocytes were cultured with 
tritiated thymidine, which was a source of low-level chronic beta radiation, and then briefly 
exposed to 1500 mGy of x rays, the yield of chromatid aberrations from the x-ray exposure was 
suppressed.  In a 1988 publication (Wolff et al. 1988) by his group, it was also demonstrated 
that human lymphocytes exposed to low doses of ionizing radiation (mild stress) became 
refractory to chemical mutagens that induced double-strand breaks in DNA. Howard Ducoff 
(1975) was the first to demonstrate radiation hormesis in insects. This author benefited greatly 
by participating in some of Dr. Ducoff’s research as a graduate student at the University of 
Illinois.  Members of this research group are now known as the Irradiating Illini.  
T.D. Luckey, in his 1991 book entitled Radiation Hormesis, reported extensive data on the 
indicated topic, including data showing that repeated mild stresses associated with chronic low-
rate exposure (involving low-LET radiation or low- plus high-LET radiation) significantly reduced 
the cancer incidence or mortality to below the level for spontaneously occurring cancers.  
Recently, such chronic radiation hormesis has been demonstrated for lung cancer in a very 
large number of epidemiological and ecological studies (Sanders and Scott 2007). 
Ullrich et al. (1976) were the first to demonstrate a pronounced radiation hormesis effect 
(for lung cancer) in gamma-ray irradiated female RFM mice.  The mice had a high spontaneous 
frequency of cancer implicating high genomic instability burdens. The pronounced radiation 
hormesis effect was similar in magnitude to the radiation hormesis demonstrated for neoplastic 
transformation by Azzam et al. (1996) for mouse embryo fibroblast cells exposed to x rays in 
vitro. Further, dose-response curves for neoplastic transformation were remarkably similar to 
those reported by Ullrich et al. (1976) for lung cancer. Just as in the Ullrich et al. study with high 
spontaneous lung cancer, there was a high spontaneous frequency of transformations for the 
mouse embryo fibroblasts, implicating a high genomic instability burden for the unirradiated 
cells. Such hormetic observations now are thought to relate to a dependency of protective 
intercellular signaling on the concentration of cells bearing genomic instability (Bauer 1996, 
2000; Portess et al. 2007; Scott 2007a,b,c). Protective signaling intensity for protective apoptotic 
pathways is thought to increase with increasing numbers of genomically unstable cells (Scott 
2004; Scott et al. 2007), i.e., a form of natural protection.  The distribution of mild radiation hits 
among the target cell population appears also to be an important determinant of the protective 
signaling intensity (Bond et al. 1987; Feinendegen et al. 2004; Rithidech and Scott 2007), 
including signaling related to induced immunity (Laster et al. 2007).   
Ullrich and Storer (1979) apparently attributed the radiation-hormesis-like observation for 
lung cancer in mice to systematic errors in lung cancer detection based on the methodology 
used.  However, such a systematic error should operate at all dose levels, including those for 
the controls; and thus correcting such an error would not be expected to eradicate the hormetic 
dose-response curve shape. This can be demonstrated by assigning an arbitrary large 
systematic error (e.g., 50%) to each dose group including the controls and correcting the data.  
When evaluating relative risk, the correction is canceled so the hormetic curve shape remains.  
In addition, the study by Ullrich et al. (1976) not only demonstrated radiation hormesis for lung 
cancer, but it was also demonstrated for reticulum cell sarcoma for both gamma-ray and 
neutron exposures. 
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Edouard Azzam (Azzam et al. 1996) and colleagues were the first to demonstrate 
radiation hormesis in vitro by exposing mouse embryo fibroblasts in culture to low doses of x-
rays.  Their findings were later confirmed by Redpath et al. (2001, 2003). Studies by 
Dr. Redpath’s group also demonstrated the importance of the type of radiation as well as dose 
rate in radiation hormesis response (Redpath et al. 2001, 2003; Ko et al. 2004, Elmore et al. 
2005; Redpath and Elmore 2007). At the encouragement of this author, Day et al. (2007) 
performed the first studies demonstrating radiation post-exposure conditioning hormesis in mice 
(prostate gland). Chromosomal inversions associated with a large radiation dose were 
completely prevented by a subsequent small radiation dose (mild stress).  Now there are many 
publications related to the indicated classes of radiation-associated hormesis (e.g., Liu et al. 
1987, 1994; Hosoi and Sakamoto 1993; Cohen 1995; Howe 1995; Khokhryakov et al. 1996; 
Wolff 1996; Jaworowski 1997, 2001; Rossi and Zaider 1997; Hashimoto et al. 1999; Tokarskaya 
et al. 1995, 1997, 2002; Redpath et al. 2001, 2003; Nyström et al. 2002; Wei and Sugahara 
2002; Liu 2003, 2004, 2007; Mitchel et al. 2003; Pollycove and Feinendegen 2003; Sakai et al. 
2003; Chen et al. 2004, Feinendegen et al. 2004; Hooker et al. 2004; Ko et al. 2004; Mitchel  
2004, 2005, 2006, 2007; Scott 2004, 2005a,b, 2007a,b,c; Scott et al. 2004; Zaichkina et al. 
2004; Elmore et al. 2005; Ina and Sakai 2005; Tubiana 2005; Tubiana et al. 2005; Boreham et 
al. 2006; Mothersill and Seymour 2006; Redpath 2006; Pollycove 2007; Portess et al. 2007; 
Sanders and Scott 2007; Scott and Di Palma 2007; Scott et al. 2007). For an extensive listing of 
the many early radiation-associated hormesis publications, see Dr. Luckey’s (1991) book 
entitled Radiation Hormesis.  
The indicated radiation-associated hormesis publications and others collectively 
demonstrate that low doses/dose rates of low-LET radiation: 
• Activate protective apoptosis signaling pathways and stimulate immunity. 
• Protect against spontaneous chromosomal damage, mutations, neoplastic 
transformation, and cancer. 
• Protect against high dose chemical- and radiation-induced cancer. 
In spite of these now widely published hormetic effects, regulatory agencies still use the 
LNT-based system for regulating human exposure to ionizing radiation and for low-dose cancer 
risk estimation. Use of the LNT-based system is considered justifiable by many outside the 
hormesis community in light of publications such as the BEIR VII Report (NRC 2006), published 
by the U.S. National Research Council/National Academy of Science. The BEIR VII report 
concluded that the LNT approach to low-dose risk assessment was valid and essentially 
dismissed radiation-associated hormesis.  A corresponding French Academies report did not 
come to the same conclusions (Tubiana 2005; Tubiana et al. 2005) when examining essentially 
the same data that were reviewed in the BEIR VII report.  The French report found hormesis to 
be plausible and the LNT risk function to be invalid for low-LET radiation doses < 100 mGy and 
especially for doses < 10 mGy. 
In the next section, three epidemiological tricks are discussed that when used helps to 
justify continued use of the LNT framework for low-dose-radiation risk assessment. An approach 
for accounting for radiation-associated hormetic effects in regulating radiation exposure is then 
discussed. 
3. Epidemiological Tricks that Favor a LNT Dose-Response Curve 
3.1 Trick #1: Throwing Away Radiation Dose 
With many previous epidemiological studies of radiation-induced cancer, the researchers 
somehow came to the conclusion that radiation dose was wasted. Thus, in order to correct for 
the so-called wasted dose, one has to lag (throw away) some of the dose. However, if the dose-
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response curve is indeed of the LNT type, then each fixed infinitesimally small increment, dD, in 
the radiation dose, D, would be expected to be associated with the exact same increment in the 
cancer risk (i.e., risk per individual).  Stated mathematically, if R(D) is the dose-dependent LNT 
risk function and D is the radiation dose and α is the slope of the LNT dose-response curve, 
then the fixed increment in risk is dR(D) = αdD; each small increment dD in the dose increases 
the risk by the amount αdD. Now there is a problem! If each increment in dose is equally 
effective in increasing risk, how can one conclude that dose is wasted? One cannot in one 
breath claim the existence of a LNT risk function, then in the next breath claim dose wasting and 
throw away dose.  It is wrong to simply throw away radiation dose in order to obtain a LNT 
dose-response curve! 
When studying DNA double-strand break induction by radiation, one usually observes a 
LNT-type dose-response curve at low doses (NRC 2006). This seems to be the basis for the 
expectation by many experts that cancer risk is also a linear function of dose.  Interestingly, no 
dose lagging is used when evaluating DNA double-strand break dose-response curves; possibly 
because the inappropriateness of doing so would be immediately realized by many if not most 
radiation researchers.  
To illustrate how radiation hormesis can be hidden by this dose lagging trick, data are 
presented in Figure 1 for in vitro neoplastic transformation after brief high-rate exposure to 
gamma rays, based on studies of Redpath et al. (2001).  The cells used were HeLa x skin 
fibroblast, and relative risk (RR) for these cells has been demonstrated to agree quite well with 
RR data for cancer (leukemia and solid tumors) induction in humans after brief high-rate 
exposure (Redpath et al. 2001).  Note the hormetic zone between 0 and 100 mGy (which 
corresponds to the hormetic zone demonstrated by Azzam et al. (1996) using x rays and mouse 
embryo fibroblast cells) where RR is suppressed to < 1. Figure 2 shows the same data as in 
Figure 1 with doses lagged by 100 mGy. The radiation hormesis has magically disappeared! 
There is no longer a hormetic zone. This dose lagging trick is still widely used in epidemiological 
studies but needs to be stopped. Publishers should no longer allow this trick to be used to 
deceive the readers and funding agencies. Use of the indicated trick contributed indirectly to the 
radiation phobia that led to more than 100,000 misinformed physician-recommended abortions 
of wanted births after the Chernobyl accident (Ketchum 1987).  
Figure 1. Relative risk dose-response relationship for gamma-ray induced neoplastic transformation 
of HeLa x skin fibroblast human hybrid cells by brief high-rate exposure, based on in vitro data from 
Redpath et al. (2001). 
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Figure 2.  Application of dose lagging (100 mGy) to the data in Figure 1. Analysis based on data 
from Redpath et al. (2001). 
3.2 Trick #2: Eliminating the Hormetic Zone via Averaging over Dose Groups 
The second trick relates to forming dose groups comprised of persons having received 
widely varying radiation doses (i.e., the minimum and maximum doses [often reconstructed] for 
each dose group differs greatly).  Such dose groups are usually necessary in case-control 
studies and are also often used in cohort studies of irradiated populations.  Here the focus is on 
case-control study design and the use of odds ratio (OR) as an estimate of RR. 
The neoplastic transformation frequency data used for the RR curve presented in Figure 1 
can also be converted to odds of neoplastic transformation and the odds used to obtain OR 
relative to controls which are point estimates (without grouping) as indicated in Figure 3. Note 
that the hormetic zone is still present and that the dose-response curve is almost identical to the 
curve in Figure 1. For low frequency stochastic biological effects, OR and RR are quite similar. 
Dose groups were then formed over the following intervals: 0 to 100 mGy, 101 to 300 mGy, 301 
to 500 mGy, and 501 to 1000 mGy. The odds for neoplastic transformation were then averaged 
over these intervals.  Then, these averages were used to calculate OR relative to the lowest 
dose group, which corresponds to the averaging carried out and methodologies employed in 
case-control studies of cancer induction.  The results obtained are presented in Figure 4, with 
the lowest dose group plotted at a dose of 0 (as is done in some epidemiological studies) and 
the results for the other dose groups plotted at the group midrange dose. Note that the hormetic 
zone has again disappeared.  Thus, odds averaging over wide dose groups when evaluating 
OR can also vanish the hormetic zone. Journal editors and the general public need to be aware 
of this averaging trick when they are told that the dose-response data from case-control studies 
are consistent with the LNT hypothesis, which implies that any amount of radiation is harmful no 
matter how small. Users of the odds averaging trick with no previous knowledge of its hormetic 
zone vanishing capabilities should be more cautious of how they interpret their research 
findings.  
Dose-grouping in cohort studies of radiation-induced cancer can also vanish the hormetic 
zone when persons who received low doses are included among the control group 
(representative of unexposed individuals).  This is because the study design has reduced power 
for demonstrating suppressed risk at low doses when irradiated persons with radiation doses in 
the hormetic zone are included in the control group (used to represent unirradiated persons).  
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Figure 3.  Odds ratio relative to controls for the neoplastic transformation data presented in Figure 1 
for gamma-ray exposure of HeLa x skin fibroblast human hybrid cells. 
Figure 4. Ratio of dose-interval-specific average odds for neoplastic transformation based on data in 
Figure 3. Ratio of average odds evaluated relative to the lowest dose group. The lowest dose group 
was plotted at dose = 0 mGy. Other data plotted at the midrange of the dose intervals are used. 
3.3 Trick #3: Constraining the Slope of the Cancer Risk Dose-response Curve to Always Be 
Positive  
A trick often employed in cohort and case-control studies is to constrain the slope of the 
dose-response curve to be positive while including high-dose, high-risk data in the analysis of 
the dose-response curve fit. This is especially true when a LNT function has been presumed to 
apply at low doses by the researchers.  Irrespective of the low-dose data, an increase in risk is 
predicted as dose increases for all such studies.  The conclusion that any dose is harmful then 
follows. Low-dose hormetic (U- and J-shaped) data departing from the LNT characteristic is 
often simply ignored.  It is wrong to portray such data as part of a LNT curve! Low-dose risk 
assessments should account for the hormetic shape to the dose-response curve. 
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4. Hormesis Implications for Regulatory Policy 
In Zbigniew Jaworowski’s1997 article, Beneficial Effects of Radiation and Regulatory 
Policy, he states the following: 
“Adaptive stimulating effects of ionizing radiation occur at near natural doses.  This disagrees 
with linear, no-threshold hypothesis on the dose/effect relationship, which is a basis of the 
current radiation protection.  Vast literature demonstrates that such effects, usually known as 
hormetic ones, occur at molecular, cellular and population levels, and often result in increased 
longevity and decreased cancer incidence… After the Chernobyl accident, adverse health 
effects and vast material losses were induced in the former USSR by practical implementation 
of the ICRP radiation protection recommendations. A revision of the current approach to 
managing the risk of ionizing radiation is needed for the public interest.” 
Here, an approach to regulating radiation exposure is recommended that allows for the 
existence of a hormetic dose zone just above natural background radiation.  The approach 
relates to the hormetic relative risk (HRR) model previously developed by this author (Scott 
2007 a,b,c), which is summarized below in a more general form. 
4.1 Hormetic Relative Risk Model 
With the HRR model for low-dose radiation-induced cancer, doses at or slightly above 
normal monthly natural background low-LET radiation levels are presumed to fall within the 
what is currently considered the hormetic zone. This hormetic zone starts at natural background 
radiation and spans a relative wide dose range, possibly exceeding 1000 mGy of low-LET 
radiation when radiation dose is delivered at a low rate.  However, protective effects associated 
with hormesis may also occur at below current natural background levels for some individuals. 
For low-LET radiation doses in the hormetic zone, cancer RR from exposure to low-LET 
radiation in excess of natural background is expected to remain < 1 for most if not all members 
of the population. Also, for combined exposure to low doses of low- and high-LET radiations 
above natural background radiation levels, the low-LET component of the dose activates 
protective hormetic processes and prevents cancer RR from increasing above 1.  The risk may 
decrease as a result of  hormetic processes that are regulated by protective intercellular and 
intracellular signaling.  
The protective signaling, presumed activated with low doses and dose rates of low-LET 
radiation, relates to removal of aberrant cells from the body via p53-dependent and independent 
apoptosis signaling pathways and stimulated immunity (Scott 2007 a,b,c; Scott and Di Palma 
2007; Scott et al. 2007). The protective signaling can also involve DNA repair pathways if a 
damage threshold is exceeded (Rothkamm and Löbrich 2003).  Possible exceptions to full 
hormetic protection are the very young and children who may not have significant burdens of 
genomically unstable cells that participate in the signaling associated with protective p53-
independent apoptosis (Scott and Di Palma 2007).   
Stochastic thresholds (StoThresh) that vary between different individuals are required in 
the HRR model for activating the protective signaling.  However, somewhat higher doses (also 
StoThresh) inhibit protection causing an increase in the RR as dose increases up to a point at 
which protection is suppressed in all individuals.  At this point, a linear response that 
extrapolates to RR = 1 at background radiation b is presumed to apply (Fig. 5).  This 
corresponds to use of the LNT model to extrapolate from high to low doses. 
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Figure 5.  Schematic representation of the hormetic relative risk model. The model is presented as a 
function of the total absorbed radiation dose D to allow for a two-dimensional representation. The 
dose scale ranges from hypothetical absolute zero natural background radiation dose ( D = 0) to 
doses in excess of the current dose b from natural background.  Doses D*, D** and D*** define the 
different dose zones indicated.  The RR at absolute zero radiation is indicated by RR*.  The 
exponential rise as dose decreases below b is supported by epidemiological data (Cohen 1995) for 
environmentally irradiated humans and is presumed to relate to reduced DNA repair capacity 
(Rothkam and Löbrich 2003), the loss of protective apoptosis (Scott and Di Palma 2007), and the 
loss of stimulation of immune functions (Liu et al. 1987). 
The mathematical functions discussed in this paper relate to radiation doses equal to or 
greater than natural background radiation. For this dose range, the indicated nonlinear hormetic 
RR(D) function (population average) can be evaluated as arising from a weighting between two 
RR(D) function components:  a LNT component (RRLNT) that applies to unprotected individuals 
and  a hormetic component (RRHORM) that applies to protected individuals.  The weighting 
function, PROTEC(D), is the probability function for activated protection (radiation hormesis) as 
a function of the dose vector, D (called a covariate dose vector by some), which relates to all 
relevant radiation doses (from low- and high-LET sources) in excess of natural background.  
PROTEC(D) represents the proportion of the irradiated population that is protected via p53-
independent apoptosis and induced immunity and is expected to depend on genetic and other 
characteristics of the population. The RR(D) for persons with the same nonzero dose vector D, 
under this model is given by 
 RR(D) = PROTEC(D)•RRHORM(D) + (1 – PROTEC(D))RRLNT(D). (1) 
Equation 1 is used to characterize the population average RR and applies to radiation doses in 
excess of natural background. Equations that relate to below natural background radiation 
exposures are not addressed in this paper.  The function RRHORM(D) = 1 - PROFAC is for doses 
in the hormetic zone and equals 1 otherwise (Scott 2007a). The protection factor (PROFAC) 
gives the expected proportion of cancer cases that are prevented due to radiation hormesis and 
only relates to the low-LET component of the total radiation dose. The PROFAC relates both to 
protective apoptosis (presumed p53-independent) and immune functioning but does not relate 
to DNA repair (Scott 2007a). The function RRLNT(D) simply adds to RR = 1 (with no radiation 
exposure) the sum K'D, where K' is a row vector of radiation-specific slope factors for excess 
cancers for matching radiation-specific doses in the dose vector D (a column vector).  For a 
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single radiation type K'D = kD, where k is the excess RR per unit dose and D is the individual 
radiation dose.  Components of the vector K' depend on DNA repair capacity (Scott 2007a) 
which is expected to be greatly reduced in below natural background radiation environments 
(Rothkam and Löbrich 2003).  Components of K' are expected to increase as DNA repair 
capacity decreases, which is expected to be the case for below natural background radiation 
exposure. For above natural background radiation exposures, components of K' are currently 
modeled as being constant.  
For just above natural background radiation exposure PROTEC(D) is evaluated presently 
as 1, decreasing only when one exits the hormetic zone (through a transition zone) at moderate 
to high doses.  For natural background radiation exposure, RR(D) = 1.  The RR dose-response 
curve associated with Equation 1 when plotted as a function of the total radiation dose 
(indicated by D in this example) has the general features as indicated in Figure 5 for doses ≥ 
natural background b. The figure however presents doses ranging from absolute zero natural 
background radiation exposure to doses considerably in excess of background radiation 
exposure.  
What has traditionally been considered the hormetic zone comprises the above natural 
background range of radiation doses for which RR < 1.  However, for doses below and above 
this zone, protective effects can be operational for some individuals.  With the HRR model, RR 
increases above 1 to RR* as the radiation dose decreases below natural background to 
absolute zero radiation, due to a progressive loss of protected individuals. Over the dose range 
for which RR < RR*, the dose-response curve is expected to have a U- or J-shape. The 
schematic exponential increase of RR in Figure 5 as dose decreases below natural background 
b is supported by data on human lung cancer mortality rates (Cohen 1995) and data revealing a 
loss of essential DNA repair capacity in low-dose radiation environments (Rothkamm and 
Löbrich 2003). 
Transition Zone A in Figure 5 is where StoThresh for activating protective signaling are 
progressively exceeded as radiation dose increases.  When protective signaling is activated in 
all members of the population, then the RR is roughly constant through what is called the Zone 
of Maximal Protection.  At doses just above this zone, StoThresh for inhibiting protective 
signaling (immune system stimulation, protective p53-independent apoptosis, but not p53-
related DNA repair) are progressively exceeded as dose increases (Transition Zone B).  At 
somewhat higher doses, protection is suppressed in everyone (except for p53-related DNA 
repair) and what is called here the Linear Zone then emerges.  This zone was previously called 
the LNT Zone because of intersection of a LNT line (Scott and Di Palma 2007), but this proved 
to be confusing terminology. The Linear Zone corresponds to the dose region where most 
epidemiological studies have mainly been conducted that claimed a LNT dose-response curve.  
For this zone, PROTEC(D) = 0, so that RR(D) = RRLNT(D).  For very high doses, departure from 
linearity can again emerge due to lethal damage to body organs such as the bone marrow. 
Over Transition Zone A, PROTEC(D) increases from zero to 1 and remains at 1 over the 
Zone of Maximal Protection. Over Transition Zone B, PROTEC(D) decreases from 1 to 0.  
4.2 Regulatory Threshold with Respect to Cancer Induction 
It is beneficial to define a regulatory radiation absorbed dose threshold (REGRADT) 
based on the StoThresh, Tj,i, for loss of protection against cancer in tissue, j, due to dose from 
the ith radiation type of interest. The indicated REGRADT can be assigned as the radiation-
specific dose that corresponds to the minimum individual dose for transitioning from the Zone of 
Maximal Protection to Zone B.  Let Tj,i,{min} represent the tissue-j-specific minimum absorbed 
dose from radiation of the ith radiation type (e.g., x rays, gamma rays, electrons, positrons, 
protons, muons, neutrons, alpha particles, fission fragments, nonrelativistic heavy nuclei, etc.), 
for Zone B.  The REGRADT is therefore determined by the most sensitive member of the 
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population, related to loss of protection over Transition Zone B. The REGRADT therefore likely 
depends on the types of radiation involved, dose rates, radiation energies, the population at risk, 
and the tissue of interest.  The dose D** in Figure 5 corresponds to the proposed REGRADT.  
Higher doses produce harm in part via loss of hormetic protection. 
One can then use the normalized stochastic effect dose, Sj, for tissue j as defined below 
to limit radiation-induced cancers (with respect to preventing excess cancers relative to the 
spontaneous frequency): 
 Sj = (Dj,1/Tj,1{min}) +( Dj,2/Tj,2{min}) + … + (Dj,n/Tj,n{min}) < 1, (2) 
for all tissues j and all n radiations of interest.  A value Sj = 0.5 means that only one half of the 
require radiation exposure for loss of adaptive protection by the most sensitive member of the 
population has occurred. 
This example does not account for genetic effects. However, it is widely known that 
genetic effects are much less likely to be induced than cancer (NRC 2006). Thus, limiting 
testicular and ovarian cancer occurrence would be expected to also limit genetic effects. There 
is also some evidence for dose-response relationships for genetic effects in humans being of 
the hormetic type with respect to low-rate exposure to gamma rays (Chen et al. 2007). Limiting 
both cancer and genetic effect occurrences would be expected to also limit shortening of life 
due to deleterious genetic effects and cancer. 
The REGRADT as defined would apply both to population and individual exposures.  
New, funded research is needed in order to properly assign appropriate values for Tj,i{min} for 
different radiations,  radiation energies (e.g., neutron energy), different cancer types, and for 
different populations. 
5. Conclusions 
There is abundant evidence for radiation-associated hormesis. However, dismissal of 
radiation-associated hormesis is in many instances based on epidemiological tricks that include 
dose lagging, odds averaging over wide dose ranges when evaluating OR, and forcing a 
positive slope to the RR dose-response curve. 
Its time for new, low-dose radiation risk assessment and regulatory paradigms that allow 
for hormesis. Normalized stochastic effects dose, based on radiation-, radiation-energy-, and 
dose-rate-specific REGRADTs could be used to limit radiation exposure. For Sj limited to < 1, 
for all tissues, cancer RR ≤ 1 would be expected. 
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Abstract 
Research is being conducted world-wide related to chemoprevention of future lung cancer 
among smokers. The fact that low doses and dose rates of some sparsely ionizing forms of 
radiation (e.g., x rays, gamma rays, beta radiation) stimulate transient natural chemical and 
biological protection against cancer in high-risk individual is little known. The cancer 
preventative properties relate to radiation adaptive response (radiation hormesis) and involve 
stimulated protective biological signaling (a mild stress response). The biological processes 
associated with the protective signaling are now better understood and include: increased 
availability of efficient DNA double-strand break repair (p53-related and in competition with 
normal apoptosis), stimulated auxiliary apoptosis of aberrant cells (presumed p53-independent), 
and stimulated protective immune functions. This system of low-dose radiation activated natural 
protection (ANP) requires an individual-specific threshold level of mild stress and when invoked 
can efficiently prevent the occurrence of cancers as well as other genomic-instability-associated 
diseases. In this paper, low, essentially harmless doses of gamma rays spread over an 
extended period are shown via use of a novel biological-based, hormetic relative risk (HRR) 
model to be highly efficient in preventing low-dose, alpha-radiation-induced lung cancer in both 
rats and humans. 
Indexing Terms: chemoprevention, cancer, radiation, hormesis, adaptive response 
1. Introduction 
Lung cancer is the leading cause of cancer death worldwide and cigarette smoking is 
considered a major risk factor. Because the population of smokers worldwide continues to be 
very large, effective lung cancer preventative modalities that could be implemented in a clinical 
setting for such high-risk individual are needed. In this paper evidence is provided that low 
doses and dose rates of sparsely ionizing gamma radiation over and extended period can 
efficiently prevent lung cancer among high-risk populations via stimulating and prolonging the 
body's natural defenses (natural chemical and biological prevention).  
Ionizing radiation has been present in the environment since the beginning of the 
universe. Radiation sources remain everywhere, including in our bodies, in our homes, in the 
soil, in plants and animals we ingest, and in the air we breathe (including polonium-210). The 
sun we depend on for sustaining life on earth is also a source of ionizing radiation, as well as 
other entities in space. It is now known that through evolution, mammalian life forms have 
developed natural cancer preventative processes (chemically and biologically regulated) that 
are stimulated by low doses and dose rates of sparsely ionizing forms of radiation (e.g., x rays, 
gamma rays, beta particles). Low doses and dose rates of these radiations stimulate protective 
intercellular and intracellular signaling that leads to activated natural protection (ANP) against 
cancer and other genomic instability associated diseases (Scott and Di Palma 2007). The 
protective signaling appears to be a generalized response to mild stress above an individual 
threshold level.  
Radiation ANP (also called radiation hormesis [Calabrese et al. 2007]) appears to be an 
evolutionary benefit of the interaction of low-level ionizing radiation with mammalian life forms 
on earth. Thus, ANP is evolutionary conserved (Mitchel 2007). High radiation doses and dose 
rates rather than preventing cancer, inhibit the protective processes that suppress cancer (Scott 
and Di Palma 2007). 
1.1 Low-Dose Radiation ANP 
Low-dose radiation ANP involves induced high-fidelity DNA repair in corporation with 
normal apoptosis (presumably p53-dependent), activation of an auxiliary protective apoptosis-
medicated (PAM) process that selectively removes precancerous (Scott et al. 2003; Scott 2004; 
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Portess et al. 2007) and other aberrant cells, and induced immune functions (Scott and Di 
Palma 2007). However, the protective processes are transient. 
Bauer (2000) has summarized what is known about the PAM process among fibroblasts 
based on numerous signaling studies by his research group. Figure 1 relates to the summary. 
The protective process involves a sophisticated system of interdependencies and interactions of 
reactive oxygen and nitrogen species. The release of transforming growth factor beta (TGF-β1) 
by transformed cells is a key early event. Nontransformed cells, when activated, release a novel 
peroxidase (P) and nitric oxide (•NO). Superoxide anions (O2-•) generated and released by 
transformed cells participate in the intercellular signaling and make transformed cells the 
selective target for intercellular induction of apoptosis (i.e., transformed cells are selectively 
removed via apoptosis). Chloride ions (Cl-) and hydrogen peroxide (H2O2) also participate in the 
intercellular signaling. The interactions of the indicated molecules result in two currently known 
major signaling pathways to protective apoptosis that are based on hypochlorous acid 
(HOCl)/hydroxyl radicals (•OH) and •NO/peroxynitrite (ONOO-). H2O2 plays a key role by 
fostering the HOCl/•OH pathway and inhibiting the •NO/ONOO- pathway. Additional pathways 
to apoptosis are likely associated with the auxiliary PAM process, with the selected path 
possibly depending on the cell type to be eliminated via apoptosis (mutants, neoplastically 
transformed cells, micronucleated cells, etc.), its local cellular environment, and the nature of 
the damage to DNA (Scott and Di Palma 2007). 
Figure 1.  Signaling pathways for the protective apoptosis mediated (PAM) process in fibroblast 
(Scott and Di Palma 2007). See main text for an explanation of symbols used. 
Stochastic threshold radiation doses (which are presumed to differ for each person and 
body organ/tissue) are required for ANP. However, somewhat higher doses can inhibit 
protective signaling (e.g., signaling related the PAM process) and also suppress the immune 
system. 
1.2 Demonstrated Benefits of Radiation ANP 
Low doses and dose rates of sparsely ionizing radiations have been found to: 
• Protect against chromosomal damage (Azzam et al. 1996 ). 
• Protect against mutation induction by a high radiation dose if given before or after the 
high dose (Day et al. 2006, 2007). 
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• Eliminate precancerous (neoplastically transformed) cells (Redpath et al. 2001). 
• Prevent chemical-induced cancer (Sakai et al. 2003). 
• Stimulate increased immune system functioning (Liu 2007). 
• Suppress cancer induction by alpha radiation (Tokarskaya et al. 1997; Sanders 
2005). 
• Suppress metastasis of existing cancer (Sakamoto et al. 1997; Sakamoto 2004) 
• Protect against diseases other than cancer (Sakai et al. 2006) 
Based on our adaptive-response research carried out over a number of years, we 
developed a biological-based, hormetic relative risk (HRR) model for cancer induction (Scott 
2007; Scott and Di Palma 2007) that accounts for radiation ANP. The current version of the 
model is discussed in the Methods section.  
2. Methods 
2.1 Computational and Statistical Approaches 
For fitting RR equations to lung cancer data for humans exposed to alpha and gamma 
radiations, Bayesian inference methods implemented via Markov chain Monte Carlo (MCMC) 
were employed, based on uniform priors for parameters to be estimated and a very long single 
chain (Scott 2007). Judgments about convergence were based on comparing the Monte Carlo 
error and posterior distribution standard deviation. Ratios of the Monte Carlo error for 
parameters to the posterior distribution standard deviation that were < 0.05 were considered 
consistent with convergence. Autocorrelation were also monitored during our MCMC runs to 
facilitate judging how long to run the chain. Where RR data were compared for different species 
(dogs, rats, humans), they were adjusted to a common baseline incidence. Standard errors for 
cancer incidence were evaluated based on the binomial distributions. Subjective upper bounds 
were used for reported zero cancer incidences. The bounds were set equal to two standard 
errors for the cancer frequency, based on 1 assigned cancer case.  
Here the focus is on application of the HRR model (Scott 2007) to lung cancer data for 
protracted exposure to low doses of alpha radiation in combination with very low doses of 
gamma rays to demonstrate the highly efficient prevention of lung cancer by gamma-ray ANP. 
Alpha radiation administered alone is a potent inducer of lung cancer. Small doses (close to 
natural background radiation levels) can cause a significant increased incidence (Lundgren et 
al. 1991; Sanders 2007). However, for combined exposure to low-dose alpha and very-low-dose 
gamma rays, the gamma-ray ANP could possibly prevents cancer induction by alpha radiation. 
The level of protection can be quantified using our HRR model. 
2.2 Hormetic Relative Risk Model 
With the current version of our HRR model, the irradiated population is separated into two 
dose- and dose-rate dependent parts: (1) those that have ANP and (2) those without ANP. For 
persons with ANP, the average cancer relative risk is given here by  
 RRANP = (1 – PROFAC)RRLNT (1) 
where RRANP is the relative risk for persons with ANP (i.e., protected individuals) and RRLNT is 
the relative risk for persons without ANP and is based on the linear-no-threshold (LNT) 
assumption. Risk is evaluated relative to an unirradiated population. Bayesian methods allow 
evaluating the expected proportion of the irradiated population that is protected for a given dose 
and dose rate and radiation combination when formally fitting the HRR model to data (Scott 
2007). 
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The protection factor (PROFAC) takes on values from 0 to 1 and here accounts for 
prevention of cancer via gamma-ray ANP. A value PROFAC=0.25 would indicate that cancer 
would be expected to be prevented in 1 in 4 individuals among those with radiation ANP. For a 
hypothetical population containing 1000 protected (by low-dose gamma-ray ANP) heavy 
cigarette smokers, if 100 were expected to develop lung cancer because of smoking, then with 
a gamma-ray PROFAC = 0.25, 25 of the 100 would be expected to be prevented from 
developing smoking-related lung cancer. Thus, not every protected person is expected to 
escape lung cancer occurrence.  
For alpha-radiation-induced lung cancer, relative risk, RRLNT can be evaluated based on a 
linear-no-threshold (LNT) function which includes the baseline cancer incidence (Scott 2007): 
 RRLNT = 1 + [(1-B)/B]KαDα , (2) 
where B is the baseline (spontaneous) cancer incidence, Kα is the presumed always-positive 
slope parameter in the HRR model and Dα is the alpha radiation dose to the target organ. 
Equation 1 is used for evaluating cancer RR for combined exposure to low-dose alpha and 
gamma rays while Equation 2 applies to exposure only to alpha radiation and relates to low, 
moderate, and high doses but not very high doses (Scott 2007). The PROFAC relates only to 
low-dose gamma rays (or a radiation type of similar interaction characteristics such as x rays 
and beta radiation when used instead of gamma rays). 
In circumstances where one has an estimate of RRANP (based on exposure to alpha plus 
gamma radiation) when every one is presumed protected and RRLNT (for exposure only to alpha 
radiation) when no one is presumed protected, you can estimate the PROFAC for a given dose 
level Dα using the baseline-independent (baseline dependence cancels) relationship: 
PROFAC = 1 – {(observed RR under alpha plus gamma irradiation)/(observed RR under 
exposure only to alpha radiation)}. 
3. Results 
3.1 Estimates of PROFAC and Kα for Different Species 
Table 1 shows PROFAC estimates ( =1) and subjective lower bounds for low-dose, low-
dose-rate, gamma-ray prevention of lung cancer among alpha-radiation exposed female Wistar 
rats that either inhaled the alpha-emitter plutonium-239 (Pu-239) alone or Pu-239 labeled with a 
gamma-ray-emitting ytterbium-169 (Yb-169) tag (label), based on studies conducted years ago 
and reported recently by Sanders (2007) that were revaluated in the context of radiation 
hormesis. Here gamma-ray doses are presumed sufficient for ANP for every rat but not high 
enough for its inhibition. Also, alpha radiation doses in Table 1are presumed not to be high 
enough to overwhelm or suppress gamma-ray-induced protective signaling. The gamma-ray 
doses in Table 1 are similar in magnitude to essentially harmless doses received form single 
diagnostic x-ray exposures. However, for the data in Table 1, the gamma-ray exposure was 
protracted over several months (physical half-life for Yb-169 = 32 d). Extending the length of 
exposure is considered to prolong the time period over which protective signaling occurs, 
thereby increasing the efficiency of protection as has been demonstrated for eliminating 
precancerous cells in vitro (Elmore et al. 2006). 
The Wistar rat lung cancer incidence data for combined alpha plus gamma radiation 
exposure is presented in Table 1. A subjective upper bound on each zero incidence is reported 
and is based on assigning 1 lung cancer case and assuming a binomial distribution for cases, 
with 2 standard errors for the assigned frequency being presented in Table 1. Calculated values 
for RRLNT based on fitting Equation 2 (re-expressed as an absolute risk) to lung cancer 
incidence data for rats exposed only to plutonium-239 (Sanders 2007) to estimate Kα are also 
included in the table and are based on the assumption that no rats were protected (i.e., 
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PROFAC = 0). The dose-group-specific excess absolute risk per unit dose was used to obtain 
six estimates of Kα that were then averaged, assuming no rats were protected. The average 
obtained for Kα was 2.1x10-4 ± 1.6x10-4 mGy1, which is close to the value of 1.2x10-4 ± 9.0x10-5 
mGy-1 previously reported for lung cancer in Mayak plutonium facility workers (Scott 2007) 
based on Equation 1 and the value of 1.0x10-4 ± 5.0x10-5 mGy-1 previously reported for lung 
cancer in F344/Crl rats that inhaled the alpha emitter Pu-239 (Scott 2007), based on studies 
conducted by Lundgren et al. (1991). Using the lowest two dose groups reported by 
Muggenburg et al. (1006) for Pu-238 alpha-particle-induced lung cancer in beagle dogs, a slope 
parameter of 1.7x10-4 ± 1.0x10-5 mGy-1 was obtained and is consistent with the result obtained 
for rats and humans.  
Table 1.  Lung cancer incidence among Wistar rats that inhaled Pu-239 + Yb-169 and 
associated expected (assuming no protection) and observed RR and related gamma-ray 
associated protection factor against cancer 
Average  
alpha 
radiation dose 
(mGy) 
Average  
gamma 
radiation dose 
(mGy) 
Number 
of  
animals 
Lung  
cancer 
incidence 
Expected 
relative 
riska 
Observed 
relative 
risk 
Protection 
factor 
0 0 1052 0.00095 ± 0.00095 1 1  
56 1 1389 0 (0.00072)b 13 0 [1]c 1.0 [0.92]d
190 2 343 0 (0.0029)b 43 0 [1]c 1.0 [0.98]d
620 1 145 0 (0.014)b 137 0 [1]c 1.0 [0.99]d
aBased on rats not exposed to gamma rays from a Yb-169 tag and Equation 2 (upper 
dashed curve in Figure 2) with RR evaluated based on B = 0.00095 rather than the value of 
0.00150 reported by Sanders (2007). 
bBionimal distribution standard error had exactly on rat developed lung cancer, given that 
none did. An average of 1.6 spontaneous lung cancers was expected among all 1677 
irradiated rats. 
cSubjective upper bound (RR = 1). 
dSubjective lower bound on PROFAC based on an upper bound of 1 for the observed RR. 
The slope parameter estimates are summarized in Table 2 and differ by less than a factor 
of 2.2. Genetic polymorphisms that impact on DNA repair efficacy are expected to impact on the 
parameters Kα and B but not the PROFAC (Scott 2007). Thus, the similar results in Table 2 for 
Kα for the different genetic backgrounds suggest that genetic polymorphisms related to DNA 
repair may not greatly impact Kα. For a point of reference, studies on relative susceptibility for 
lung cancer occurrence for pair-wise comparisons for different genetic polymorphisms that 
impact on DNA repair show relative susceptibility factors < 1.5 (Hu et al. 2004; Hung et al. 2005; 
Benhamou and Sarasin 2007; Schwartz et al. 2007). Genetic polymorphisms that impact on the 
PAM process and immune system functioning are expected to influence the PROFAC and B but 
not Kα. 
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Table 2.  Evidence for slope parameter Kα for lung cancer induction being similar for different 
species and rodent strains. 
Animals Radiation Types Kα in mGy-1 
Equation 
Used 
Estimated or implicated 
value for PROFAC 
Humans Alpha + gamma 1.2x10-4 ± 9.0x10-5 Equation 1 0.86 ± 0.07 
F344/Crl rats Alpha + gamma 1.0x10-4 ± 5.0x10-5 Equation 2 0 (high dose data only)a
Wistar rats Alpha 2.1x10-4 ± 1.6x10-4 Equation 2 0 
Beagle dogs Alpha + gamma 1.7x10-4 ± 1.0x10-5 Equation 2 0 (high dose data only)a
aThe protective signaling induced by low-dose gamma rays is assumed to be inhibited or 
overwhelmed by very high doses of alpha radiation. 
Note from Table 1 that the very small, essentially harmless protracted gamma-ray doses 
(1 to 2 mGy) appeared to completely prevented (PROFAC = 1.0) the occurrence of lung 
cancer (spontaneous and alpha-radiation-induced) for alpha radiation doses up to 620 mGy. 
However, subjective lower bound on PROFAC presented in Table 1 would allow for a 
possible lower level of protection (PROFAC as low as 0.92).  
Where the RR was expected to be 137 in the absence of ANP (Table 1), based on data for 
exposure only to alpha radiation (presumably unprotected rats), adding an essentially harmless 
protracted gamma-ray dose (1 mGy) appears to have protected against 100 % of the expected 
lung cancers. Thus, all of the gamma-ray irradiated rats were apparently very well protected 
from lung cancer occurrence for the alpha radiation dose range (0 to 620 mGy) in Table 1. A 
similar level of protection might be expected against smoking-related lung cancer in humans. 
The indicated level of protection is even higher than we previously reported (PROFAC = 
0.86 ± 0.07 [Scott 2007]) for Mayak plutonium facility workers that were chronically exposed 
over years to alpha and gamma radiation in connection with the production of plutonium-239 for 
use in nuclear weapons. The workers inhaled Pu-239 and were also exposed to external 
gamma-ray sources (Khokhryakov et al. 1996). However, not only did the gamma rays appear 
to protect against low-dose alpha-radiation-induced lung cancer among Mayak facility workers, 
but also against cigarette-smoking related lung cancers (Scott 2007). Many of the male workers 
were heavy smokers (Tokarskaya et al. 2002). 
3.2 Lung Cancer RR Dose-Response Relationships for Different Species 
Figure 2 shows the lung cancer RR data for combined alpha and gamma-ray exposure of 
Wistar rats and beagle dogs. The Wistar rat data of Sanders (2007) for exposure only to alpha 
radiation are also included for comparison and to demonstrate the dramatic protection 
implicated to be associated with low-dose gamma-ray exposure when the alpha radiation dose 
is less than about 1000 mGy (1 Gy). The beagle dog data are from Muggenburg et al. (1996) 
and relate to inhalation exposure to the alpha emitter Pu-238 in an insoluble oxide form with a 
Yb-169 gamma-ray tag. The observed RR values for dogs and for Wistar rats exposed only to 
alpha radiation were adjusted so as to be applicable to a baseline cancer incidence of 
95/100,000 =0.00095 as was reported for Wistar rats exposed to both alpha and gamma 
radiations (Sanders 2007). Thus, relative risk is expressed based on a common baseline. For 
making the indicated adjustments, it was assumed that the PROFAC = 0 for the alpha-irradiated 
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dogs, because of the mainly very high radiation doses involved. Similarly PROFAC was 
assumed equal to zero for Wistar rats exposed only to alpha radiation.  
Figure 2.  Lung cancer relative risk: Wistar rats that inhaled Pu-239 + Yb-169 (filled squares) based 
on data from Sanders (2007); adjusted RR for Wistar rats for inhalation exposure to only Pu-239 
(filled circles) based on data from Sanders (2007) after adjusting to a baseline of 95/100,000; 
Expected adjusted RR for Mayak plutonium facility workers (filed diamonds) exposed via inhalation 
to Pu-239 in combination with external gamma rays, based on fitting data from Kokhryakov et al. 
(1996) and adjusting for a baseline to 95/100,000; adjusted RR for Beagle dogs(closed triangles) 
that inhaled Pu-238 in an insoluble form based on data from Muggenburg et al. (1996) after 
adjusting to a baseline of 95/100,000. Logarithmic scales are used on both axes. The upper dashed 
curve though the rat data for Pu-239 only (open circles) is based on Equation 1. Values for RR = 0 
are plotted at RR = 0.1. The zero dose-group for which RR = 1 is excluded. The horizontal line is for 
RR = 1. 
Note that the adjusted RR in Figure 2 seemed to converge for the different species an 
approach an asymptotic value as the alpha radiation dose increased above 10,000 mGy 
(10 Gy). The mainly very high alpha radiation doses received by dogs (500 to 340,000 mGy) 
appear to have completely inhibited or overwhelmed protective signaling associated with 
gamma-ray ANP. 
Human lung cancer RR data in Table 3 from Khokhryakov et al. (1996) could not be 
directly adjusted (since PROFAC > 0 implicated) for a baseline of 95/100,000 but were fitted to 
Equation 1 [work previously carried out Scott 2007)] assuming alpha radiation doses for each 
dose group were uniformly distributed over the dose intervals indicated and gamma-ray doses 
were negligible, except for their influence on protective signaling which is accounted for via 
PROFAC. All exposed workers were assumed to be protected by gamma-ray ANP for the range 
of alpha radiation doses in Figure 2. The simulated lower smooth curve for humans in Figure 2 
is based on Bayesian analysis posterior mean values previously obtained for model parameter 
Kα (=1.2x10-4 ± 9.0x10-5 mGy-1) and PROFAC (= 0.86 ± 0.07) in fitting the data in Table 3 via 
Markov chain Monte Carlo (Scott 2007). The MCMC analysis comprised 1 million iterations with 
the first 800,000 results discarded as burn-in. For the results for humans in Figure 2, the 
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baseline B was fixed at 95/100,000. The upper dashed curve in Figure 2 for exposure only to 
alpha radiation also applies to humans and was obtained by setting PROFAC = 0. 
Table 3.  Unadjusted lung cancer RR for Mayak plutonium facility workers based on data 
from Khokhryakov et al. (1996) 
Alpha Radiation 
Dose Range  
(mGy) 
Mean Baseline 
Incidence per  
100,000a 
Observed 
Unadjusted 
RR 
Expected 
Unadjusted RR, 
HRR Modelb 
Expected 
Adjusted RR, 
HRR Modelc 
0 – 2 41 ± 25  0.39 0.36 ± 0.07 0.24 ± 0.07 
12.1 – 50 57 ± 41 0.53 0.56 ± 0.09 0.40 ± 0.07 
   51 – 200 76 ± 55 1.58 1.59 ± 0.14 1.30 ± 0.12 
 201 – 800 86 ± 93 4.65 4.66 ± 0.23 4.24 ± 0.21 
 801 – 3200 99 ± 106 28.1 28.1 ± 0.53 29.2 ± 0.55 
aBased on Russian national statistics (Khokhryakov et al. 1996) 
bBased on unadjusted results from previous application of HRR model to these data using 
Bayesian inference methods to address stochastic thresholds for ANP and for protection 
inhibition (Scott 2007). 
cExpected RR based on the HRR model when the baseline B=95/100,000 (same as for 
Wistar rats exposed to Pu-239 + Yb-169). 
All results presented in Figure 2 therefore relate to a common baseline incidence, B = 
95/100,000. Table 3 also provides predictions for the adjusted lung cancer RR for humans 
based on B = 95/100,000 with doses assumed uniformly distributed over the group-specific 
dose intervals indicated in the table. Evaluations were carried out via MCMC analysis based on 
posterior distributions for model parameters Kα and PROFAC. This was achieved by rerunning 
the MCMC analysis previously used to estimate HRR model parameters but this time also 
making prediction of RRANP for B = 95/100,000. The results in Table 3 suggest that low 
baselines B can obscure the reduction in lung cancer RR associated with low-dose ANP. 
Alpha radiation doses > 2000 mGy appeared to have inhibited protective signaling (e.g., 
related to the PAM process) for rats and dogs and the same is implicated for humans based on 
the convergence of the dose-response data (for protected and unprotected groups) at high 
doses. 
3.3 Gamma-Ray ANP for Humans vs. Rats 
Protection provided to humans and Wistar rats by low-dose/low-dose-rate gamma-ray 
ANP can be assessed relative to the upper dashed curve and filled circles in Figure 2 that relate 
to only alpha radiation exposure. Humans appear to be somewhat less protected than were 
Wistar rats, even when the uncertainty in PROFAC for rats (Table 1) is considered. Many of the 
male Mayak facility workers were heavy smokers and this may have impacted on the level of 
ANP-related protection that occurred. Genetic differences may also be important. 
The results in Figure 2 are consistent with the view that low doses and dose rates of 
gamma rays activate the body’s natural defenses (biological and chemical protection), which in 
turn can significantly reduce the risk of cancer from exposure to carcinogenic doses of other 
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agents. Similar results have been demonstrated for suppression of chemical-induced cancer via 
low-dose-rate exposure to sparsely ionizing radiation (Mitchel et al. 1999; Sakai et al. 2003). For 
alpha radiation doses > 2000 mGy in Figure 2, there is no evidence for gamma-ray ANP. This 
suggests that deleterious biological signaling associated with very high alpha radiation doses 
may overwhelm or suppress protective signaling in all mammalian species (including humans) 
that is associated with low dose gamma-ray ANP. 
4. Implications for Other Radiations and Other Diseases 
Gamma rays, x rays, and beta radiation have similar physical characteristic with respect to 
their interacting with biological tissue. Thus, extended exposures to essentially harmless low 
doses of any of these sparsely ionizing radiations would also be expected to efficiently stimulate 
protective signaling associated with ANP against lung cancer. Repeated (over and extended 
period) very small x-ray doses could be administered from machines in hospitals used for 
administering diagnostic x-ray procedures. Beta radiation sources used in nuclear medicine 
could also be administered in very small harmless quantities in clinical settings for achieving 
ANP against future cancer for high risk groups of adults. Special radiation ANP rooms (e.g., 
exercise, lounges) with elevated background radiation (e.g., from potassium-40) could be used 
in medical facilities for implementing natural protection from lung cancer for long-time heavy 
smokers.  
Most children are unlikely to be at high-risk for cancer. Thus, using low-dose-radiation 
ANP to prevent cancer among children may be inappropriate in most cases. 
The indicated low-dose radiation ANP is not restricted to preventing lung cancer but could 
be implemented in a clinical setting to possibly prevent any type of cancer for high-risk adults as 
well as for other genomic-instability associated diseases.  
Many other agents are also being researched related to possibly preventing lung and 
other cancers among high risk populations and individuals. It may be beneficial to consider 
combining low-dose radiation (harmless doses) with other cancer preventative agents, but new 
funded research is needed in this area. 
5. Conclusions 
The results presented demonstrate that low doses of gamma rays when spread over time 
are a potent inducer of natural chemical and biological protection against lung cancer. Because 
gamma rays, x rays, and beta radiation have very similar physical characteristics related to their 
interaction with biological tissue, low x-ray and beta-radiation doses when spread over time 
(e.g., repeated very low doses of x rays, or continuous very-low levels of beta irradiation) are 
also expected to be potent inducers of natural chemical and biological protection against lung 
cancer. Similar protection is also expected against other types of cancer and for other genomic-
instability-associated diseases. 
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